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CHAPTER 1 
 
Tumor associated macrophages as a potential target for nanoparticle-mediated, 
anti-tumor immunomodulation 
Tumor associated macrophages (TAMs) play an important role in establishing a pro-tumorigenic 
local microenvironment in many tumor types. These macrophages stimulate angiogenesis, promote tumor 
growth and metastasis, and suppress the normal immune response.5, 6 TAMs display a phenotype that is a 
blend of the two classical macrophage phenotypic categories. Like the classically immunogenic (M1) 
macrophage, TAMs produce low levels of inflammatory cytokines which creates pro-tumorigenic 
smoldering inflammation.7 Like the classical description of a tissue remodeling (M2) macrophage, TAMs 
break down the surrounding extracellular matrix, secrete growth factors, and inhibit the adaptive immune 
response.2 
It has been demonstrated that tumor associated macrophages are a viable therapeutic target in 
cancer treatment and ablating these cells can have a powerful anti-tumor effect.4 A more elegant solution 
would be to target these pro-tumor macrophages with a therapeutic agent that can alter their behavior to a 
strongly immunogenic phenotype capable of stimulating tumor immunity. In order to facilitate this 
immunological engineering, a target for phenotypic modulation must be elucidated. The NF-κB pathways 
control macrophage phenotype and the inflammatory response.8 Tumor cell induced NF-κB deregulation 
has also been implicated in creating many of the pro-tumor traits of TAMs.9 By selectively manipulating 
NF-κB in TAMs, it should be possible to eradicate the TAM phenotype and recapitulate the normal immune 
response. 
siRNA is a potent therapeutic agent that can selectively knock down the translation of specific 
mRNA into protein.10 Clinical trials of siRNA therapeutics utilize targeted nanoparticles as a delivery 
device to reach specific cell populations.11 A mannose functionalized nanoparticle with an siRNA 
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condensing region can target the macrophage mannose receptor (upregulated in TAMs) and deliver NF-κB 
specific siRNAs in order to change the TAM phenotype.12, 13  
Tumor associated macrophages (TAMs) as a therapeutic target for cancer treatment 
 The tumor supportive stroma has been identified as an attractive target for therapeutic intervention 
in breast cancer. In particular, macrophages have been implicated in supporting tumor associated 
angiogenesis, promotion of local tumor growth and invasion, tumor cell migration, intravasation, and 
suppression of an anti-tumor immune response.1, 5, 6 Macrophages play an important trophic role in tissue 
development and one suggested mechanism for the TAM phenotype is that these  roles are recapitulated in 
the tumor microenvironment.14 An increase in TAMs at the site of tumor progression has proven to be 
predictive of poor prognosis and survival in mouse models of human breast cancer.15, 16  
Over expression of one of the major 
factors controlling macrophage maturation, 
CSF-1 (M-CSF), has been associated with poor 
prognosis in breast, ovarian, prostate, 
hepatocellular, and colorectal cancer.1, 17 One 
of the more insidious characteristics of TAMs 
driven in part by CSF-1 is their ability to 
prepare a metastatic niche for circulating tumor 
cells (Figure 1.1).1 Ablation of CSF-1 in the 
polyoma middle T oncogene (PyMT) mouse 
model of human breast cancer greatly reduces 
macrophage density in the tumor, resulting in a 
decreased rate of tumor progression and an 
inhibition of metastases.18 In addition to data from studies of CSF-1 in cancer, CCL-2, a major macrophage 
chemotaxis factor has been shown to be upregulated in a wide range of cancers, and is associated with poor 
 
Figure 1.1: Macrophages are recruited to the pre-metastatic 
niche by secreted products from the primary tumor. Once 
tumor cells arrive at the metastatic site, they recruit 
macrophages from the blood. These macrophages 
accumulate, and promote tumor cell survival and growth. 
Figure adapted from source #4. 4  
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prognosis in breast cancer.17  Depletion of macrophages reduces tumor growth in melanoma, ovarian 
cancer, Lewis lung carcinoma, and prostate tumor graft models.1 All of this evidence supports the role of 
TAMs as a viable therapeutic target for treating breast cancer. Furthermore, unlike tumor cells, the genomes 
of macrophages are stable; they may not become resistant to therapy as readily as tumor cells. 
Defining the TAM phenotype 
TAMs are phenotypically distinct from the classic M1/M2 description of macrophage phenotype, 
but blend together several characteristics of both. In the classic description of macrophages, M1 or 
‘classically activated’ macrophages are thought of as the pro-inflammatory, immune response-controlling 
macrophages. M1 activation is associated with an increase in inflammatory cytokines IFN-γ, TNF-α, IL12, 
chemoattractants for CD8+ T-cells, and reactive oxygen species. This phenotype describes a cell that acts 
as a first responder to the site of injury or microorganism invasion and controls local inflammation and the 
total immune response.2 M2 or ‘alternatively activated’ macrophages exhibit an increase in scavenger and 
mannose receptors, an increased production of anti-inflammatory cytokines IL-10 and IL-1 receptor 
antagonist, and an increased production of T-regulatory cell chemoattractant, CCL-22.2 The M2 phenotype 
describes a cell that tunes and inhibits inflammation and the adaptive immune response as well as promotes 
tissue repair, angiogenesis and tissue remodeling facilitated by increased production of MMP-1 and MMP-
9.19 Many, if not all of these key properties of M2 macrophages are present in TAMs. Alberto Mantovani 
and collaborators have published a model of TAMs as an M2 macrophage; a summary of their findings are 
depicted in Figure 1.2. 
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Initially, it appears as if the M2 
phenotype is a perfect model for the 
TAM phenotype. However, the M2 
phenotype cannot account for one of the 
defining characteristics of TAMs: 
smoldering inflammation. Smoldering 
inflammation is a pro-tumorigenic state 
characterized by low levels of local 
inflammation combined with a 
paradoxical blunting of innate and 
adaptive immunity.7, 20 While in a state 
of smoldering inflammation, a pre-
cancerous niche is constantly exposed to 
reactive oxygen species (ROS), which 
react with DNA in the surrounding cells resulting in permanent genomic alterations, but not enough to 
result in cell death. In addition to low levels of ROS and other inflammatory cytokine production, TAMs 
produce migration inhibitory factor (MIF), a cytokine that overcomes p53 function by suppressing its 
transcriptional activity.21 These phenotypic traits are usually associated with M1 macrophages. 
The TAM phenotype does not map cleanly onto the classical M1/M2 description of macrophages. 
Instead it displays a blended phenotype in which traits from both M1 and M2 macrophages are selected to 
create a strongly pro-tumor microenvironment. TAMs produce growth factors to promote tumor cell 
growth, tissue remodeling, and angiogenesis. They suppress the immune response to tumor cells while 
simultaneously creating low levels of local inflammation. When taken together, these traits show that TAMs 
play a critical role in tumor progression, summarized in Figure 1.3. 
 
Figure 1.2: TAMs as polarized M2 macrophages. TAMs are a 
source and target for cytokines and chemokines in the tumor 
microenvironment. These molecules and other local mediators 
regulate tumor growth, progression and invasion, interaction with 
other stromal components, and the activation and orientation of 
adaptive immunity. Figure adapted from source #2.2  
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NF-κB deregulation in macrophages creates a pro-tumor environment 
 NF-κB is a transcriptional pathway that has been studied for over 25 years and is known to regulate 
hundreds of genes. This pathway is active in many cell types and plays a major role in controlling the 
inflammatory response in macrophages in particular.8 Investigations of NF-κB activation in solid tumors 
have revealed a critical role for NF-κB in linking inflammation with tumor development.20 In myeloid cells 
such as macrophages, the inflammatory state is controlled by NF-κB activation which is essential for the 
inflammatory macrophage phenotype.22 NF-κB activation is needed to create many of the traits of TAMs 
including the critical smoldering inflammation state.17 The total effect that NF-κB activation in 
macrophages has on the tumor microenvironment is complicated. The NF-κB pathway is actually 
comprised of the two parallel pathways seen in Figure 1.4.3 The classical pathway is well understood and 
has been studied in great detail; however, the alternative NF-κB pathway remains critically understudied, 
and the effects that alternative NF-κB activation has in specific cell populations is not well understood.23  
 
 
Figure 1.3: Six macrophage functions that provide support to a tumor. All of these 
macrophage subtypes are defined by the expression of canonical markers CD11b, F4/80, 
and CSF-1R, and the absence of Gr1, but they are educated by the tumor cells to adopt 
a TAM phenotype and perform the tasks shown. Figure adapted from source #1.1  
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 It is well established that the classical 
NF-κB pathway controls the classical 
immune response of activated macrophages 
as well as many other non-immunogenic 
macrophage behaviors. The classical 
pathway is activated by binding of ligands to 
toll-like receptors at the cell surface, and by 
inflammatory cytokines such as 
lipopolysaccharide and tumor necrosis factor 
family members.3 In response to these 
stimulatory signals, the classical NF-κB 
pathway causes macrophages to produce 
more inflammatory cytokines and recruit 
cells of the innate and adaptive immune 
system to the site of activation. The classical 
pathway also exhibits a low level of 
constitutive activation in mature 
macrophages. In contrast, alternative 
pathway function is far more selective and 
specific than classical NF-κB activation. Alternative activation of NF-κB in activated macrophages is 
poorly understood relative to the classical pathway but it is broadly known to play an important role in 
organogenesis and tissue architecture organization.23, 24 The alternative pathway is not constitutively active 
in normal macrophages and is held in abeyance by sequestration and constant degradation of its activating 
kinase, NIK, by TRAF3.25 Signal induced activation of protein kinases is usually mediated through post-
translational modifications; however, NIK is unique in that its function is controlled by a steady level of 
expression. The expression level of NIK is normally kept low and bound by TRAF3, but is drastically 
 
Figure 1.4: Classical (left) and alternative (right) pathways of 
NF-κB activation. The classical pathway is induced by most 
physiological NF-κB stimuli and is represented here by 
TNFR1 signaling. In the classical pathway, IκB-α is 
phosphorylated in an IKKβ and NEMO-dependent manner, 
which results in the nuclear translocation of mostly p65- 
containing heterodimers. In contrast, the alternative pathway, 
induced by certain TNF family cytokines, such as RANKL, 
involves IKKα-mediated phosphorylation of p100 associated 
with RelB, which leads to partial processing of p100 to p52 
and the generation of transcriptionally active p52-RelB 
complexes. Figure adapted from source #3.3  
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elevated in response to a specific alternative NF-κB activating signal.26 In the tumor microenvironment 
signals such as TNF family members, inflammatory cytokines, and other cytokines such as M-CSF and IL-
10 stimulate macrophages to undergo broad NF-κB activation. Though the NF-κB pathways are functioning 
normally, the activation of the pathways is deregulated by the tumor cells; the tissue remodeling effects of 
alternative NF-κB activation would be tumorigenic in this context.9, 27  
 The NF-κB pathways together produce complex pro- or anti-inflammatory and pro- or anti-
tumorigenic effects. The interplay between the two pathways is made more confounding in that there is 
some unknown level of cross talk between the two, resulting in activation or depression of one or both 
pathways in different circumstances. This inherent complexity makes NF-κB a useful tool for tumor cells 
to utilize via local deregulation using tumor secreted cytokines, but it also makes NF-κB a very desirable 
target to manipulate in order to activate the innate cytotoxic, immunogenic properties of mature 
macrophages. One potential approach for manipulation of NF-κB in macrophages to create an anti-tumor 
environment is to selectively activate the strong immunogenic response associated with normal classical 
pathway activation while simultaneously turning off the tissue remodeling effects associated with the 
alternative pathway. This method of turning off one pathway while activating the other would rob the tumor 
of its supportive macrophages, reduce the complexity of NF-κB cross talk in TAMs, and create an anti-
tumor phenotype in resident macrophages. Ideally, these macrophages would be capable of direct 
phagocytosis of tumor cell related materials (tumor cells and microvesicles), release apoptotic signals, and 
recruit CD8+ T-cells and other activated immune cells to the tumor microenvironment. 
Manipulating NF-κB by transfecting macrophages with siRNA 
 NF-κB is a promising therapeutic target for manipulation of macrophage phenotype to induce anti-
tumor behavior. However, a broad, untargeted manipulation of NF-κB would likely result in negative side 
effects and would not produce the precise activity required to induce an anti-tumor phenotype in 
macrophages. In order to deliver a therapeutic agent to this specific cell population, a targeted delivery 
method would be ideal.28 In a current collaboration between the Giorgio, Yull, and Duvall laboratories, a 
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novel mannosylated nanoparticle has been developed. This particle targets the mannose receptor found on 
the surface of macrophages and upregulated in TAMs.12, 29 The core of the particle is created by RAFT 
polymerization of BME, PAA, and DMAEMA to create a hydrophobic, terpolymer with tunable endosomal 
escape properties.30, 31 Next, a polycationic DMAEMA block is added by RAFT polymerization to add the 
capability to condense polyanionic therapeutics onto the particle.  Finally, an AzEMA block is polymerized 
onto the diblock polymer to form a triblock polymer terminated in an AzEMA block to support further 
functionalization. In order to create a mannose functionalized polymer, click chemistry is performed with 
alkyne –functionalized mannose to attach a mannose moiety to the end of the polymer.13, 32 The completed 
polymer assembles into positively 
charged micelles when reconstituted in an 
aqueous solution, forming mannosylated 
nanoparticles (MnNP; Figure 1.5). 
siRNAs are short therapeutically 
active RNA strands that knock down the 
translational activities of specific mRNAs 
without significant off-target side 
effects.33 siRNA knocks down levels of 
target proteins by binding to 
complementary mRNA strands, resulting 
in the degradation and/or inactivation of 
the target mRNA strand.10 Far from being 
just a laboratory tool, siRNA has been 
shown to have clinical translational potential, and targeted delivery of therapeutic siRNA has been 
accomplished in humans.11, 34 As a therapeutic agent with tunable activity and high specificity, this 
polyanion is well suited for incorporation into MnNP to be used to target and treat TAMs in vivo. 
 
Figure 1.5: Schematic representation of the endosomal-escape 
polymeric nanoparticles for mannose receptor-targeted delivery 
of siRNA. 
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Furthermore, because mature macrophages are largely non-proliferative, delivered siRNA would not be 
diluted by cell division. There are many commercial transfection agents, such as Lipofectamine, with the 
ability to deliver siRNA to cells in vitro; however, MnNP have a more neutral surface charge, indicating 
potential in vivo biocompatibility. Macrophages are notoriously difficult to transfect, but this vehicle is 
uniquely suited for use in experiments targeting TAMs in in vivo models of cancer and delivering NF-κB 
modulating siRNA sequences.  
Hypothesis and Specific Aims 
 The hypothesis of this work is that mannosylated, endosomal escape nanoparticles can be used to 
target tumor associated macrophages and deliver siRNA to manipulate NF-κB activation in macrophages 
with the intent of activating tumor immunity. This work is a collaborative effort between multiple research 
groups with expertise in the areas of nanotechnology, polymer chemistry, molecular biology, mouse models 
of cancer, and cancer immunology. The combined effort of these groups has resulted in the completion of 
collaborative research that could not be performed by any single group alone. 
Aim #1: Develop an efficacious in vitro protocol for transfecting macrophages with siRNA using MnNP 
and screen NF-κB specific siRNA sequences. 
Aim #2: Determine optimum targets in the NF-κB pathways and analyze the potential therapeutic effects 
of knocking down those targets with MnNP-delivered siRNA. 
Aim #3: Demonstrate the targeted delivery of nucleotides by MnNP in an in vivo mouse model of a solid 
cancer with a significant TAM population. 
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CHAPTER 2 
  
In vitro optimization of macrophage transfection using commercial and nanoparticle 
transfection agents 
Introduction 
Recent decades have bought great advances in gene therapy technologies, specifically the 
emergence of siRNA. siRNAs can be used to inhibit the translation of specific mRNAs without significant 
off-target side effects by RNA interference (RNAi).33 RNAi results in loss of target protein expression by 
siRNA binding to complementary mRNA strands, leading to mRNA degradation.10 The clinical translation 
potential of siRNA has been demonstrated by the targeted delivery of therapeutic siRNA in humans.11, 34 
Another advantage of siRNA is that the degree of knockdown can be tuned to varying degrees of specificity, 
potency, duration by taking advantage of the transient nature of siRNA inhibition.35 One of the current 
obstacles therapeutic siRNA faces is the delivery of active siRNA to specific cells types. Free siRNA is 
rapidly degraded in vivo by circulating RNases In addition, the strong polyanionic charge and significant 
molecular mass limits cellular entry of unformulated siRNA. An siRNA delivery vehicle that provides 
preferential localization to particular tissues and/or target cell types as well as superior siRNA protection 
and cellular entry is required for optimal and spatially specific RNAi. 
Targeted nanoparticles have been used in clinical trials of siRNA therapeutics as a delivery device 
to reach specific cell populations.31 The generation of a charge-neutral or near-neutral surface of a 
nanoparticle carrier of siRNA improves biocompatibility, as well as allowing for the potential attachment 
of a targeting ligand to the surface of the particle, improving cellular specificity. To address this, we have 
developed and characterized a tri-block polymer nanoparticle that specifically targets TAMs for siRNA 
delivery. The particle is designed such that the pH responsive core disrupts the endosomal compartment 
upon cellular uptake, rupturing the organelle as the internal pH drops and releasing the functional siRNA 
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into the cytoplasm.36-38 One advantage of this core block design is its self-assembly into particles in an 
aqueous solution due to its tunable hydrophobicity.39 The second block is a poly(DMAEMA) polymer with 
a polycationic charge that condenses polyanionic oligonucleotides within the particle and serves to carry 
and protect siRNA for delivery to a target cell. A distal, azide-presenting block serves as a modular platform 
for further functionalization with targeting ligands or other biomolecules of interest and represents novelty 
in the nanoparticle synthesis scheme relative to our previous work.  
Using ‘click’ chemistry, we have functionalized the surface of these nanoparticles with a mannose 
ligand (MnNP) to specifically target TAMs via the mannose receptor, CD206.13 The mannose receptor is 
highly specific to mature macrophages and has been shown previously to be upregulated on the surface of 
TAMs.12, 29, 40 The mannose receptor is an endosomal, pattern recognition receptor which, when present at 
high levels, participates in suppression of the classical immune response.40, 41 We have shown previously 
that uptake of these mannosylated endosomal escape nanoparticles (MnNP) by macrophages is mannose 
dependent and that uptake of MnNP is enhanced in macrophages compared to uptake of untargeted, 
hydroxyl capped nanoparticles (OHNP).13 MnNPs are systematically designed to condense and shield 
siRNA in the interior of the particle for optimal systemic transport, enter the tumor vasculature via the 
enhanced permeability and retention (EPR) effect, specifically target TAMs in the tumor 
microenvironment, and escape the low pH late endosome to deliver functional siRNA into the cytoplasm. 
Materials and Methods 
 Cell culture. Unless otherwise stated, all primary cells and cell lines used in this study were 
maintained in DMEM (Corning, MT-10-13-CV) with the addition of 10% (vol:vol) FBS and 1% Pen Strep 
(Gibco) at 37°C in a 5% CO2 humidified atmosphere. 
Bone marrow derived macrophage (BMDM) culture. Bone marrow derived macrophages 
(BMDMs) were made by harvesting bone marrow from wild type and NGL mice on an FVB background. 
Cells from NGL mice produce luciferase and GFP as a readout of total NF-κB activation. The media for 
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these cells contained 10% (vol:vol) FBS, 1% Pen Strep (Gibco), 5% heat inactivated horse serum (Gibco), 
1% MEM non-essential amino acid mixtue (Sigma), 50 µM 2-mercaptoethanol (Sigma), and was 
supplemented with media from L-129 fibroblasts as a source of M-CSF.42 The bone marrow was cultured 
for 6 days in the M-CSF supplemented media and the resultant BMDMs were scraped from their plates and 
re-plated as necessary for further experiments. 
Luciferase activity readout in reporter cells. For cells producing luciferase as a readout of total 
NF-κB activation, the Promega luciferase assay system with reporter lysis buffer was used to measure 
luciferase activity. Plated cells were frozen in 1x reporter lysis buffer, then went through a thaw-freeze-
thaw cycle before being scraped from the plates, and centrifuged at 13,000 rpm for 4 minutes. 20 µl of the 
supernatant was added to 100 µl of the luciferin substrate, and the resulting luminescence was counted to 
determine luciferase activity. 
TNF-α stimulation of cultured macrophages. In order to induce NF-κB activation in 
macrophages, NGL BMDMs were stimulated with 0.01-1000 ng/ml of TNF-α (Peprotech) for 6 hours. 
After 6 hours, NF-κB activation was assessed by luciferase assay. For subsequent experiments including 
TNF-α stimulation, 10 ng/ml concentrations were used. Because transfection of cells can be improved in 
some cases by utilization of serum-free media, the possibility of coincident transfection and stimulation 
was investigated by stimulating NGL BMDMs with TNF-α (10 ng/ml, 6 hrs) in serum-free conditions. 
Stimulation efficacy was assessed by luciferase assay.  
NF-κB activation in macrophages with tumor treated media. The HLL macrophage cell line is 
a line of immortalized macrophages that produces luciferase as a readout of total NF-κB activation. HLL 
macrophages were plated in the wells of 12-well plates at a density of 300,000 cells/well (approximately 
80,000 cells/cm2). Tumor cell treated media was produced by culturing PYG 129 polyoma tumor cells, 
L129 polyoma tumor cells, and ID8 ovarian tumor cells in media for 3 days.43-45 The HLL macrophages 
were exposed to the tumor cell treated media for 1, 6, and 18 hours. As a control for different methods of 
NF-κB-related macrophage stimulation, cells were also stimulated with TNF-α (10 ng/ml) (Peprotech) or 
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lipopolysaccharide (LPS, 100 ng/ml) (Sigma) and interferon-γ (IFN-γ, 20 ng/ml) (Peprotech). After 
incubation with the tumor cell treated media, the HLL macrophages were analyzed for total NF-κB 
activation by measuring luciferase activity. 
Luciferase knockdown in NGL reporter BMDMs with siRNA delivered by HiPerFect. NGL 
BMDMs were plated in 12-well plates at a density of 300,000 cells per well (approximately 80,000 
cells/cm2). Anti-luciferase siRNA (50 µM stock solution) (Life Technologies, AM4629) was added to 3, 6, 
10, and 20 ul of HiPerFect (Qiagen) and allowed to form complexes for 1 hour. After complex formation, 
siRNA-HiPerFect complexes were added to the cell culture media for a final siRNA concentration of 10 
nM. The cells were transfected for 24 hours. To induce NF-κB activity and luciferase production, the cells 
were stimulated for 6 hours with TNF-α (10 mg/ml) and luciferase activity was measured. 
Assessment of siRNA mediated NF-κB knockdown using anti-IKKβ and anti-p52/p100 
siRNA. NGL BMDMs were plated in 12-well plates at a density of 300,000 cells per well (approximately 
80,000 cells/cm2). In order to assess the efficacy of the purchased siRNA sequences (Life Technologies), 
anti-IKKβ siRNA (s68173) and anti-p52/p100 siRNA (s70545) were complexed with HiPerFect for a total 
dose of 10 nM siRNA, 20 µl HiPerFect per well. A scrambled siRNA sequence (4390846) was used as a 
negative control for siRNA activity and unloaded HiPerFect was used (20 µl per well) as control for 
macrophage stimulation by the transfection agent. Luciferase siRNA was delivered as a positive control. 
The cells were transfected for 24 hours. The last 6 hours of transfection included concurrent stimulation 
with TNF-α. Total NF-κB knockdown was assessed by luciferase assay. 
Fabrication of nucleotide loaded MnNP. MnNP were fabricated as previously described.13 
Briefly: the core of the particle is created by RAFT polymerization of butyl methacrylate (BMA), 2-
propylacrylic acid (PAA), and 2-(Dimethylamino)ethyl methacrylate  (DMAEMA) to create a hydrophobic, 
terpolymer with tunable endosomal escape properties. Next, a polycationic DMAEMA block is added by 
RAFT polymerization to add the capability to condense polyanionic therapeutics onto the particle.  Finally, 
a 2-Azidoethyl methacrylate (AzEMA) block is polymerized onto the diblock polymer to form a triblock 
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polymer terminated in an AzEMA block to support further functionalization. In order to create a mannose 
functionalized polymer, click chemistry is performed with alkyne –functionalized mannose to attach a 
mannose moiety to the end of the polymer. The completed polymer assembles into positively charged 
micelles when reconstituted in an aqueous solution, forming mannosylated nanoparticles. 
 For experiments using MnNP to deliver siRNA or short, fluorescently labeled DNA strands, MnNP 
polymer was reconstituted in sterile PBS at a concentration of 4 mg/ml and sonicated for 10 minutes. The 
MnNP in aqueous solution were used immediately or stored in aliquots at -20 °C. For complexation with 
the MnNP, all nucleotides were diluted to 50 µM in sterile, nuclease-free water. In order to form MnNP-
nucleotide complexes with the optimal N:P ratio as described in our previous work, the 4 mg/ml MnNP 
solution was combined with 50 µM nucleotide solution in a 2:1, vol:vol ratio (160 ng of MnNP polymer 
per pmol of siRNA). The nucleotides were allowed to complex with the MnNP for 1 hour at room 
temperature, then used in in vivo and in vitro experiments. Nucleotide loaded OHNP were also formulated 
using this protocol. 
Protein level analysis of siRNA mediated knockdown using different transfection agents. In 
order to investigate the comparative knockdown efficacies of different transfection agents, knockdown of 
the luciferase reporter for NF-κB activity in NGL BMDMs was assessed by luciferase assay. To prepare 
samples for luciferase assay, NGL BMDMs were plated in 12-well plates at a density of 300,000 cells per 
well (approximately 80,000 cells/cm2). Anti-luciferase siRNA was complexed with HiPerFect, 
Lipofectamine, OHNP, and MnNP and delivered to the cells at an siRNA concentration of 10 nM. The cells 
were transfected for 24 hours. The last 6 hours of transfection included concurrent stimulation with TNF-
α. Total NF-κB knockdown was assessed by luciferase assay.  
 Analysis of nanoparticle transfection in serum-free conditions. To assess the effect of 
nanoparticle-delivered, siRNA mediated knockdown in serum-free conditions NGL BMDMs were plated 
in 12-well plates at a density of 300,000 cells per well (approximately 80,000 cells/cm2). Cells were 
transfected with anti-luciferase siRNA delivered by MnNP, OHNP, and Lipofectamine at 10 nM for 24 
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hours in serum-containing and serum-free media. The last 6 hours of transfection included concurrent 
stimulation with TNF-α. Total NF-κB knockdown was assessed by luciferase assay. 
Nanoparticle uptake time course. Wild type BMDMs were cultured in normal media and media 
containing IL-4 (10 ng/ml) (Peprotech) for 72 hours. IL-4 stimulation has been reported to induce an M2-
like phenotype in macrophages and increase mannose receptors on the cell surface.46 The cells were then 
plated in 96-well plates at a density of 50,000 cells per well (approximately 350,000 cells/cm2). A 21 base 
pair, Cy3-labled DNA sequence was purchased from Sigma for complexation with MnNP. The sequence 
was designed to have the same base pair order and charge characteristics as the scrambled siRNA sequence 
from Life Technologies. The Cy3_DNA were complexed with MnNP and OHNP and the complexes were 
delivered to the BMDMs. Cy3 fluorescence was measured at 0.5, 1, 3, 5, 10, and 18 hrs by washing the 
cells with PBS 3x and then measuring fluorescence with a Tecan Infinite M1000-Pro plate reader as a 
measurement of particle uptake. The dataset was analyzed using a two-factor analysis of variance 
(ANOVA) to determine if significant differences existed within the dataset. Post hoc analysis was 
performed using two-tailed T-tests for pairwise comparisons between selected groups. The probability for 
type I error in the post hoc analysis was reduced by minimizing the number of paired comparisons using a 
priori knowledge of the relationships between groups and selecting only the most pertinent comparisons. 
siRNA sequence screen using Lipofectamine. Several siRNA sequences against NF-κB proteins 
were purchased from Life Technologies. The siRNA targets and serial numbers are summarized in Table 
2.1. The siRNA were complexed with Lipofectamine and delivered to NGL BMDMs (12 well plates, 
300,000 cells per well (approximately 80,000 cells/cm2), 4 samples per conditions) for 24 hours at an siRNA 
concentration of 10 nM. The most successful sequences were then used at 50 nM and delivered to NGL 
BMDMs using both Lipofectamine and MnNP. For both studies, the effects of the siRNA on total NF-κB 
activity was assessed by luciferase assay following TNF-α stimulation of the cells. 
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Table 2.1: siRNA targets and serial numbers of siRNA sequences purchased from Life Technologies 
siRNA Target Serial Number 
scrambled sequence 4390846 
GAPDH 4390849 
Luciferase AM4629 
IKKβ (A) s68173 
IKKβ (B) s68174 
IKKβ (C) s68175 
p52/p100 (A) s70545 
p52/p100 (B) s70546 
p52/p100 (C) s70547 
p65 (A) s72857 
p65 (B) s72858 
p65 (C) s72859 
IκBα s70548 
 
Rapid adhesion enrichment of TAMs. In order to enrich the TAM population from solid 
mammary and ovarian tumors, the tumors were removed and homogenized in cell culture media with 
Collagenase A (5 mg/ml, Roche) and DNaseI (5 mg/ml, Roche) for 2 hours. After 2 hours of incubation 
with gentle rocking, the homogenate was filtered through 70 micron filters and the cells were pelleted via 
centrifugation at 1000 g for 10 minutes. The pellet was then resuspended in 2 ml of ACK red blood cell 
lysis buffer (Gibco) for 2 minutes. The cell suspension was then diluted to 20 ml, pelleted, and the pellet 
resuspended in culture media. The tumor homogenate was then added to 6- or 12-well plates with 10 
million, or 3 million cells per well, respectively. The homogenate was incubated in the welled plates for 45 
minutes, and the non-adhered cells vigorously washed from the wells with PBS (3 washes), leaving the 
macrophages adhered to the plate at approximately 80-90% confluence.47-51  
In vitro transfection of murine mammary PyMT TAMs. Spontaneously arising murine 
mammary tumors were harvested at a palpable stage from 12 week old mice with a mammary epithelium 
targeted polyoma middle T oncogene (PyMT, FVB strain background).52 TAMs were enriched into 12-well 
plates with a 45 minute, rapid-adhesion protocol. After the TAMs were isolated, they were transfected with 
FAM-labeled, scrambled siRNA (Ambion) for 2 and 6 hours using MnNP, alcohol-capped (non-targeted) 
endosomal escape nanoparticles (OHNP), or Lipofectamine. A control set of TAMs were incubated with 
free, FAM-labeled siRNA alone. After transfection, the cells were gently washed three times with sterile 
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PBS and fixed in 4% paraformaldehyde for 30 minutes at 4°C. FAM fluorescence was measured in each 
sample with a Tecan Infinite M1000-Pro plate reader as an indicator of siRNA delivery with 12 
measurements per well in a filled circular pattern. The dataset was analyzed using a two-factor analysis of 
variance (ANOVA) to determine if significant differences existed within the dataset. Post hoc analysis was 
performed using two-tailed T-tests for pairwise comparisons between selected groups. The probability for 
type I error in the post hoc analysis was reduced by minimizing the number of paired comparisons using a 
priori knowledge of the relationships between groups and selecting only the most pertinent comparisons. 
  
Results and Discussion 
 Bone marrow derived macrophages (BMDMs) as a model for TAMs. It has been reported that 
BMDMs are a viable, in vitro model for TAMs.15 BMDMs are made from myeloid progenitor cells 
harvested from femoral bone marrow and matured in media supplemented with M-CSF. In vivo, M-CSF is 
a potent macrophage recruiting and maturation cytokine and is known to play a role in the recruitment of 
myeloid progenitors into tumors, and maturing these cells into macrophages.17 In order to measure 
knockdown of NF-κB activity by siRNA, it is necessary to ensure that there is a measurable signal to 
knockdown. After 6 hours of incubation in TNF-α treated media, total NF-κB activity increased in dose 
dependent manner as measured by luciferase readout as a proxy measure of NF-κB activity (Figure 2.1A).  
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 LPS treatment of the HLL cell line microphages induces a strong response as measured by 
luciferase assay as a readout of NF-κB activity, however, the results of treatment with TNF-α and tumor 
cell treated media is not as clear. Though it appears that TNF-α stimulates both pathways in a manner 
similar to stimulation with tumor treated media (Figure2.1B), it is possible that this observation is an artifact 
created by the low luciferase production of the HLL cells. There is some activation of HLL activity using 
TNF-α and tumor treated media, the magnitude of the response indicates that this particular cell line is not 
optimum for resolving small increases in NF-κB activation. Future studies should endeavor to reproduce 
these results in a different reporter macrophage, such as NGL BMDMs. 
Screening NF-κB specific siRNA sequences for efficacy, using commercial transfection 
agents. In order to confirm that purchased siRNA could knock down NF-κB activity in macrophages, 
several sequences were screened in NGL BMDMs. MnNP fabrication, validation, and optimization had not 
finished, so commercial transfection agents were used to screen the siRNA sequences. Initially, HiPerFect 
was used as the commercial transfection agent. Product information for HiPerFect claims that it is a blend 
  
Figure 2.1: Activation of NF-κB in BMDMs by TNF-α and other stimulating agents. (A) Activation by TNF-α is dose 
dependent, with the dose response leveling off at approximately 10 ng/ml of TNF-α. (B) LPS in combination with IFN-γ 
induces strong NF-κB activation. This combination of molecules is known to activate the classical pathways. In contrast, 
activation with TNF-α, which activates both pathways, produces a lower amount of total NF-κB activity. Activation by 
TNF-α induces levels of activity similar to activation stimulated by tumor cell treated media from 3 tumor cell lines (L129 
and PYG – murine mammary tumor cells, ID8 – murine ovarian tumor cells). 
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of neutral and positively charged lipids and is able to transfect difficult to transfect cells such as 
macrophages with less toxicity than other commercial transfection agents. Upon the addition of the 
polyanionic nucleotide strand, the lipids form a micellular structure with the nucleotide encapsulated in the 
particle.  
The amount of HiPerFect to be used for transfection was optimized by delivering anti-luciferase 
siRNA to stimulated NGL BMDMs and measuring knockdown of luciferase activity. 20 µl of HiPerFect 
per ml of media was found to produce the strongest knockdown using 10 nM siRNA (Figure 2.2A). These 
parameters were then used to test initial siRNA sequences for IKKβ in the classical NF-κB pathways and 
p100/p52 in the alternative pathway. IKKβ is an activating kinase for the classical pathway which 
phosphorylates the inhibitor protein bound to p50:p65 heterodimer. Knockdown of IKKβ should reduce 
activation of the classical pathway, mitigating the smoldering inflammation caused by TAMs. p100 is one 
of the transcriptionally active NF-κB proteins. A portion of this protein acts as the inhibitor of the alternative 
pathway and is degraded upon pathway activation. The resulting p52:RelB heterodimer is then free to 
undergo nuclear translocation. By knocking down p100/p52, alternative NF-κB signaling should decrease. 
It is my hypothesis that a decrease in alternative activation will decrease or remove the support that TAMs 
provide to tumor cells. Although these parameters resulted in 85% knockdown of luciferase activity using 
an anti-luciferase siRNA, knockdown of IKKβ resulted in 18% knockdown of total NF-κB activity and 
p100/p52 knockdown resulted in 40% knockdown of NF-κB activity. These percentages indicate some 
degree of success in decreasing NF-κB using the screened sequences, but the amount of HiPerFect required 
to achieve this knockdown rendered extended use of HiPerFect financially infeasible. Lower amounts of 
HiPerFect did not produce efficacious knockdown of NF-κB activity. 
20 
 
 
Lipofectamine was selected as a more cost effective commercial transfection agent as an alternative 
to HiPerFect. The transfection ability of Lipofectamine was tested by performing a screen of siRNA 
sequences for IKKβ, p100/p52, and p65 (RelA). p65 is one of the transcriptionally activating proteins of 
the classical NF-κB pathway. It is normally bound in heterodimers with p50 and is activates hundreds of 
gene targets, including those associated with both strong and smoldering inflammation. Knockdown of p65 
in TAMs should reduce smoldering inflammation in the tumor stroma. Furthermore, p65 is downstream 
from IKKβ, which has significant cross-talk with other intracellular pathways; therefore, targeting p65 
should have fewer off-target effects than targeting IKKβ. 
  
Figure 2.2: (A) Knockdown of luciferase in NGL BMDMs using HiPerFect with 10 nM anti-luciferase siRNA is dependent 
on the amount of HiPerFect used to deliver the siRNA. (B) Knockdown of total NF-κB activity by 10 nM siRNA with 20 
ul/ml HiPerFect in NGL BMDMs. Knockdown of the model protein, luciferase, was satisfactory, but knockdown of total 
NF-κB by delivering siRNA for IKKβ and p52/p100 was less than desired. 
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 Using Lipofectamine as the transfection agent, efficacious siRNA sequences were confirmed for 
the NF-κB related proteins shown in Figure 2.3. Transfection with IKKβ siRNA significantly reduced total 
NF-κB activity by approximately 40% for sequences B and C. Similar significant reduction in activation 
(40-45%) was measured following transfection with p65 siRNA sequences B and C. This level of 
knockdown in consistent with the strategy of delivering siRNA to reduce activation of a single pathway, 
which would leave the unaffected pathway free to normally respond to stimuli. It is interesting to note that 
knockdown of the alternative pathway with p52/p100 specific siRNA sequences (B and C) resulted in a 70-
80% decrease in total NF-κB activity following TNF-α stimulation. From this result, it can be inferred that 
there is possibly a mechanism of direct or indirect cross-talk between the two pathways or that TNF-α 
stimulation of NF-κB activation in these cells was driven largely by the alternative pathway and the siRNA 
sequences for this pathway were very effective. These results indicate that knockdown of the classical 
pathway with siRNA may only affect that one pathway, while knockdown of the alternative pathway using 
siRNA may reduce activation of both pathways.  
It is known that products of one NF-κB pathway can potentially activate the other; in particular, 
the TNF family of proteins.3 It is possible that knocking down the alternative pathway is reducing the 
production of some cytokine that stimulates the classical pathway or that stimulates other pathways which 
 
Figure 2.3: Knockdown of total NF-κB by Lipofectamine delivered siRNA sequences. Single factor ANOVA 
confirms significant differences within the data set (P < 0.0001). T-tests for significance compare TNF-α 
stimulated BMDMs to siRNA transfected BMDMs (control). * : P ≤ 0.05, ** : P ≤ 0.01. 
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in turn activate classical NF-κB. Another possible explanation hinges on the fact that NF-κB activation can 
be accomplished with protein dimers other than p50:p65 and p52:RelB. It is possible that by knocking down 
p52, p52:p65 heterodimers, which could be activated by classical signaling, are also reduced. It is also 
possible that reduction of p52 activates a compensatory mechanism and results in more production of p105, 
which is degraded to p50; although there is currently no direct evidence for this mechanism. An increase in 
p50 could result in the formation of p50 homodimers, which are known to inhibit classical activation.53  
Efficacy of MnNP as a transfection agent for macrophages. After the change was made from 
HiPerFect to Lipofectamine as the commercial transfection agent of choice, an experiment to compare all 
of the transfection agents at once was performed. Luciferase activity in stimulated NGL BMDMs was 
knocked down using 10 nM anti-luciferase siRNA delivered by both of the commercial agents and by 
targeted and untargeted nanoparticles. All of the transfection agents created significant knockdown of 
luciferase activity (Figure 2.4), with Lipofectamine producing the strongest knockdown. Importantly, this 
was the first test of the MnNP and OHNP delivery agents, both of which produced significant knockdown 
even though they were used following a protocol optimized for the commercial transfection agents.  
 
In order to improve transfection efficacy by MnNP, alterations to the commercial agent optimized 
protocol were investigated. In some cases, transfection under serum-free conditions can improve 
 
Figure 2.4: Knockdown of luciferase activity by anti-luciferase siRNA delivered 
by different transfection agents in TNF-α stimulated BMDMs. Dunnett’s test for 
significance compare TNF-α stimulated BMDMs to siRNA transfected BMDMs. 
* : P < 0.01. 
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transfection efficiency by removing the charged serum proteins that can potentially interact with the 
charged particle surface, reducing particle functionality or marking the particles for complement mediated 
immune clearance. Figure 2.5A shows that TNF-α stimulation of BMDMs, the model used for NF-κB 
activation in macrophages, is altered by serum-free conditions. Furthermore, transfection under serum-free 
conditions is less physiologically relevant than performing transfections in serum containing media. In vivo 
transfection of cells brings the transfection agent into contact with blood serum proteins, which is an 
important consideration when designing a therapeutically relevant nanoparticle transfection agent. 
However, as Figure 2.5B shows, MnNP (and OHNP) are designed such that the presence of serum proteins 
in the transfection media do not significantly reduce the knockdown effect mediated by the nanoparticle 
delivery device.  
 
 Once it was determined that serum-free conditions would not improve the transfection efficacy of 
MnNP, increasing the concentration of the delivered siRNA and MnNP delivery agent was investigated as 
a potential method of improving knockdown of NF-κB in macrophages. 50 nM siRNA was delivered to 
BMDMs for 24 hours by MnNP and Lipofectamine and knockdown of total NF-κB was analyzed following 
TNF-α stimulation. The most successful sequence for each protein from Figure 2.3 was delivered to the 
  
Figure 2.5: The effects of serum on BMDM stimulation and transfection. (A) Serum-free media decreases TNF-α 
activation of BMDMs. Knockdown of NF-κB in BMDMs is easier to measure given a strong initial signal. Any 
decrease in activation will increase the difficulty of measuring the knockdown effect of siRNA. Activation of NF-κB 
in serum-free conditions is sub-optimal for measuring the effects of siRNA. (B) The use of serum-free media does 
not significantly improve knockdown of luciferase by anti-luciferase siRNA delivered by nanoparticle transfection 
agents or Lipofectamine. Though in some cases, serum-free conditions can improve transfection, using serum-free 
conditions will not improve transfection of BMDMs by MnNP, OHNP, or Lipofectamine. 
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BMDMs. As Figure 2.6 shows, MnNP-mediated, siRNA knockdown of total NF-κB activity was similar to 
Lipofectamine-mediated knockdown. Total NF-κB activity was significantly decreased upon MnNP 
delivery of siRNA sequences. For all future in vitro experiments utilizing MnNP, a 50 nM concentration of 
siRNA was used with a corresponding increase in MnNP concentration. Also noteworthy is that the average 
knockdown of total NF-κB activity by Lipofectamine-delivered siRNA was less than the knockdown from 
10 nM siRNA. It is possible that this decrease in efficacy is due to an increase in cytotoxicity associated 
with increasing the amounts of the strongly positively charged lipids making up the Lipofectamine 
formulation. 
 
 We have previously shown that uptake of MnNP is mannose dependent, and that uptake can be 
reduced by introducing free mannose during transfection, which competes with the MnNP for uptake by 
the macrophage mannose receptor.13 To investigate the differences between untargeted, hydroxyl capped 
nanoparticles, OHNP, and MnNP, Cy3 labeled dsDNA was loaded into the particles and delivered to 
BMDMs for 18 hours. Two different populations of BMDMs were used: normal BMDMs and BMDMs 
stimulated with IL-4 to increase mannose receptor production.46 Particle uptake by BMDMs was measured 
 
Figure 2.6: MnNP-delivered, 50 nM siRNA knockdown of total NF-κB 
activity is comparable to knockdown achieved by using Lipofectamine. In 
addition to exhibiting efficacious delivery and knockdown characteristics, 
MnNP are designed to be biocompatible both in vitro and in vivo. Dunnett’s 
teats for significance compare TNF-α stimulated BMDMs (Blank, control) to 
siRNA transfected BMDMs. * : P ≤ 0.05, + : P ≤ 0.01 
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at various time points by measuring Cy3 fluorescence in the BMDMs. In IL-4 stimulated macrophages, 
uptake of MnNP is significantly increased as compared to uptake of MnNP in unstimulated macrophages 
(Figure 2.7). Uptake of OHNP is not significantly different between the two groups of cells. This result 
indicates that the mannose ligand on the surface of the MnNP is mediating enhanced uptake that is specific 
for macrophages that have undergone phenotypic differentiation by IL-4. 
 
 
 
Figure 2.7: Nanoparticle uptake time course in IL-4 stimulated and unstimulated BMDMs.  
Analysis of variance indicates significant differences within the data set (P<0.001) (A) Uptake 
of MnNP in IL-4 stimulated BMDMs was significantly greater than uptake in unstimulated 
BMDMs after 18 hrs. Uptake of MnNP under both conditions was significantly greater than 
uptake of OHNP after 5 and 18 hours. (B) Earlier time points of nanoparticle uptake are 
highlighted. Uptake of MnNP occurs as early as 30 minutes after administration. Uptake of 
MnNP is significantly greater than uptake of OHNP after 1 hour. T-tests for significant 
differences in group averages were performed between multiple experimental groups. † , ‡ : P 
≤ 0.05,  * or + : P ≤ 0.001. 
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 Although IL-4 stimulated BMDMs are reported to have increased mannose receptor production, 
unstimulated BMDMs also express this receptor at their surface. This explains why, even at earlier time 
points, MnNP uptake is enhanced relative to OHNP uptake in both IL-4 stimulated and unstimulated 
BMDMs. Significant uptake of MnNP occurs as early as 30 minutes after administration to IL-4 stimulated 
BMDMs. This rapid uptake is consistent with endosomal uptake of the particles, in this case mediated by 
the mannose receptor. These results also indicate that the particles can be taken up to some small extent in 
a non-specific manner. It is likely that some particles are phagocytized by the macrophages or taken up via 
other, non-specific endosomal pathways. 
 
A final experiment investigating the mechanism of MnNP delivery to macrophages compared 20 
hour MnNP delivery to Lipofectamine delivery. Both transfection agents were labeled with Cy3_dsDNA. 
After 20 hrs of incubation, Cy3 fluorescence was measured as an indicator of particle uptake and the percent 
of Cy3 positive cells was determined from fluorescent and bright-field images of the cells. Figure 2.8A 
shows that transfection with MnNP resulted in significantly more uptake of Cy3 labeled nucleotide than 
transfection with Lipofectamine. Furthermore, Lipofectamine transfects a larger population of cells with 
Cy3 labeled nucleotide, but the total fluorescence delivered is approximately half that delivered by MnNP. 
Compared to Lipofectamine, MnNP strongly transfect a smaller subset of macrophages. This is consistent 
 
Figure 2.8: (A) Transfection of BMDMs with MnNP resulted in significantly more uptake of Cy3 labeled nucleotide than 
transfection with Lipofectamine after 20 hours. (B) MnNP transfect a smaller subset of cells than Lipofectamine. 
Lipofectamine transfects a larger population of cells with Cy3 labeled nucleotide, but the total fluorescence delivered is 
approximately half that delivered by MnNP.  
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with the mechanism of MnNP transfection being a more targeted delivery to cells expressing the 
corresponding surface receptor. This combined with our previous report that uptake of MnNP is mannose 
dependent indicates that MnNP are targeting a subset of macrophages with greater amounts of mannose 
receptor. This result highlights the potential for MnNP to target the appropriate subset of macrophages in 
vivo. Macrophages (and TAMs) with a tissue remodeling/immunoinhibitory phenotype have increased 
mannose receptor production. This effect is so pronounced that the presence of high levels of mannose 
receptor in macrophages is a commonly used indicator for this macrophage phenotype. 
MnNPs enhance in vitro delivery of fluorescently labeled siRNA to TAMs ex vivo. 
Spontaneously arising murine mammary tumors were harvested from 12 week old mice containing a 
mammary epithelium targeted polyoma middle T oncogene (PyMT).52 The tumors were dissociated and the 
resident TAMs from the tumor homogenate were enriched.47-51 TAMs were transfected with FAM-labeled 
siRNA for 2 or 6 hours with either MnNP, hydroxyl-capped (non-targeted) endosomal escape nanoparticles 
(OHNP), or Lipofectamine (Figure 2.9).  
After 6 hours of transfection, TAMs exposed to MnNP-siRNA_FAM had significantly higher FAM 
fluorescence than TAMs transfected with Lipofectamine (1.6-fold increase in FAM fluorescence vs 1.25-
fold increase). Furthermore, fluorescence measured in TAMs transfected with the non-targeted OHNP was 
not significantly different than the fluorescence measured in TAMs transfected with the highly cationic 
Lipofectamine (also possessing no specificity for TAMs). For all samples, siRNA delivery increased from 
2 to 6 hours, with the greatest increase occurring in the MnNP transfected samples. The rate of MnNP 
uptake by the TAMs is also increased at the 2 hour time point compared to the untargeted transfection 
agents. I observed a burst effect in delivery during the first few hours in the MnNP transfected samples 
indicating rapid, mannose-mediate uptake. Without the aid of transfection complexes, a small amount of 
free siRNA is taken up by the TAMs. This is likely due to phagocytosis of the siRNA molecules by the 
macrophages following binding of serum proteins to the siRNA. It is important to note that while 
unmodified siRNA may be taken up by cells in a non-specific manner both in vitro and in vivo, siRNA 
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delivered in this fashion exhibits little to no activity. The transfection efficacy of the untargeted nucleotide, 
OHNP and Lipofectamine, are similar. Previously, we have demonstrated enhanced siRNA delivery to 
murine BMDMs ex vivo by MnNPs to be mannose dependent. Results of this study, with TAMs, are 
consistent with earlier findings confirming MnNP recognition by CD206 in BMDMs.13  
 
 
Conclusions 
 Mannosylated nanoparticles are capable of delivering functional siRNA to macrophages in vitro. 
While initial experiments used HiPerFect as a commercially available comparison for MnNP, it was later 
deemed unfeasible for continued use and Lipofectamine was chosen as a replacement. MnNP are capable 
of delivering functional siRNA for NF-κB proteins to macrophages, and the total reduction of NF-κB 
activity is comparable to that achieved with Lipofectamine delivery. The MnNP have the added trait of 
being specifically designed to be compatible with in vivo use. Investigations into the practical aspects of 
using MnNP to transfect macrophages resulted in the conclusion that the particles can be used effectively 
in serum containing media and that knockdown of NF-κB activity is best observed under pathway 
 
Figure 2.9: In vitro transfection of TAMs isolated from murine mammary PyMT tumors with MnNP results in greater 
uptake of FAM labeled siRNA as compared to other transfection agents. Analysis of variance indicates the presence of 
significant differences within the dataset (P<0.001). MnNP creates a significantly greater increase in FAM fluorescence in 
the TAMs from the 2 hr to the 6 hr time point as compared to Lipofectamine or the non-targeted OHNP (*,†, ‡: P < 0.05) 
and the high rate of change of FAM fluorescence in these cells indicates a rapid burst effect in delivery using MnNP. The 
two non-targeted agents have similar delivery efficacies. 
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activating conditions, such as TNF-α stimulation of the macrophages: the effect of siRNA is more evident 
when there is a strong signal to knockdown. 
 MnNP are taken up to a greater degree in macrophages with increased mannose receptor presence 
(induced by IL-4 stimulation) compared to wild type macrophages. The enhanced uptake of MnNP by IL-
4 stimulated macrophages compliments our previous results indicating that MnNP uptake is mannose 
dependent. Furthermore, uptake of untargeted particles by IL-4 stimulated macrophages was not different 
from uptake of the same particles by wildtype macrophages. There is greater overall uptake of the MnNP 
than the OHNP, and uptake of MnNP occurs at earlier time points. A comparison of MnNP and 
Lipofectamine revealed that MnNP strongly transfect a small population of macrophages in the BMDM 
population, while Lipofectamine moderately transfects a larger population of BMDMs. Comparisons 
between MnNP and non-specific transfection agents were confirmed in an enriched TAM population. 
Significant uptake of MnNP in TAMs occurs earlier than non-specific agents and there is a burst effect in 
the rate of change of particle uptake that is only seen with MnNP transfection at early time points. 
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CHAPTER 3 
  
In vitro manipulation of NF-κB in macrophages using MnNP delivered siRNA results in a 
potentially anti-tumor phenotype 
Introduction 
Immunotherapy as a treatment for cancer is seeing a resurgence. Many therapeutic strategies, such 
as adoptive T-cell transfer for prostate cancer, focus on activating or enhancing adaptive immunity against 
cancer cells.54, 55 However, cells of the innate immune system are also an attractive target. Tumor associated 
macrophages (TAMs) have been implicated as one of the most prevalent and impactful types of immune 
cells in the tumor related stroma.1, 2, 56 In most cases, the genetic material of TAMs is stable and free of 
mutations, but interactions between the tumor cells and the resident or infiltrating macrophage population 
have caused the macrophages to adopt a phenotype characterized by the constant production of low levels 
of inflammatory cytokines.15 This produces a state of smoldering inflammation in the tumor and 
surrounding tissue. This type of inflammation is not strong enough to induce apoptosis or other mechanisms 
of cell death in the tumor cells, but is significant enough to cause survivable DNA damage in the tumor 
cells’ genetic material as well as activate survival signals in the nearby cells.7, 20 Paradoxically, TAMs also 
produce immunosuppressive cytokines, such as IL-10, which suppress the ability of resident immune cells 
to act against the invading tumor cells and prevents the recruitment of CD8+ T-cells, NK cells, and other 
cytotoxic or pro-inflammatory immune cells.57-59 Furthermore, TAMs produce growth factors and can 
degrade surrounding connective tissue and induce angiogenesis, allowing the primary tumor to grow.52, 60, 
61 Finally, TAMs participate in the metastatic process by creating pathways which aid tumor cell 
intravasation.4, 18 
 It has been reported that the tumorigenic and metastatic effects generated by TAMs can be reduced 
or removed by ablating macrophages with liposomal clodronate in mouse models of human cancer.18 
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Though TAMs have adopted a pro-tumor phenotype, as macrophages they have the potential to produce 
cytotoxic levels of inflammation, lyse surrounding cells, and coordinate an immune response from cells of 
the innate and adaptive immune system.42, 43, 62, 63 The ability to recapitulate these cytotoxic and 
immunostimulatory functions in TAMs, creating an anti-tumor phenotype, would be a powerful therapeutic 
tool for treating tumors and metastases known to have a significant macrophage population. This anti-tumor 
phenotype could be produced by strategically manipulating the NF-κB pathways in TAMs. The NF-κB 
pathways are potent controllers of macrophage phenotype and regulate many of the inflammatory and 
trophic functions of macrophages.64-66  
 Although the classical NF-κB pathway is a constitutively active survival pathway, strong, acute 
activation of the classical pathway by inflammatory molecules such as LPS or TNF-α creates a pro-
inflammatory phenotype in macrophages.67-69 In contrast, the alternative NF-κB pathway is activated by a 
narrower set of molecules; primarily the tumor necrosis factor family of cytokines (RANKL, CD40L, 
TWEAK, TNF-α).23 Activation of the alternative NF-κB pathway in macrophages has been shown to be 
necessary for the formation of lymph nodes and Peyer’s patches. Mice without functioning alternative NF-
κB pathways in macrophages also have disorganized splenic and thymic architecture.70, 71 The mechanisms 
and down-stream effects of NF-κB activity in TAMs is not completely understood, but the current 
understanding of the ultimate effect of NF-κB activation in solid tumors is that it contributes to both 
smoldering inflammation and to tumor-sustaining effects. 
 In the past, the prevailing wisdom regarding NF-κB activity in tumors has been that activation of 
these two pathways in the context of primary or metastatic tumors creates strong pro-tumor effects.44 
However, given the current understanding of the effects of NF-κB activation in specific cell populations, 
this theory is too generalized. Recent work in mice with activatable classical NF-κB signaling in 
macrophages has shown that strategic activation of the classical pathway profoundly reduces metastatic 
tumor burden in a tail-vein injected mouse model of metastatic breast cancer. This reduction in lung 
metastases could be explained by the increase in mRNA for inflammatory cytokines and T-cell recruitment 
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cytokine, CXCL9, and a decrease in mRNA for molecules associated with tissue remodeling and 
suppression of immune activity.43 This highlights the therapeutic potential of strategically activating NF-
κB in TAMs in order to activate an acute, strong inflammatory phenotype. 
 Ideally, a strategy for activating anti-tumor immunity in TAMs would decrease the supportive 
effects these cells have on the tumor, and simultaneously activate a potent immune response to the tumor 
cells, leveraging both the innate and adaptive immune systems. A potential mechanism for creating this 
effect is knocking down alternative NF-κB activation and increasing classical NF-κB activation in TAMs. 
The therapeutic agent used to achieve this effect should be highly specific for the target NF-κB components 
and should create a strong, targeted, transient effect: it would be counter-productive to create weak 
inflammation or permanent, strong inflammation at the site of the tumor, or to cause systemic inflammation.  
I have screened several NF-κB specific siRNA sequences using both the commercial transfection 
agent, Lipofectamine, as well as MnNP. Initially, my strategy was to knock down both classical and 
alternative activation in order to reduce pro-tumor TAM effects. During the course of the study, I discovered 
that siRNA against the inhibitor protein of the classical pathway activates the classical pathway, potentially 
inducing a pro-inflammatory, immunogenic phenotype in the transfected macrophages. Here I detail my 
work validating the efficacy of MnNP as transfection agents for delivering siRNA designed to knockdown 
IκBα, which I hypothesize will activate classical NF-κB signaling. Finally, I investigate the potential 
therapeutic efficacy of using MnNP-delivered siRNA to activate the classical NF-κB pathway or to knock 
down the alternative NF-κB pathway in macrophages. 
Materials and Methods 
Cell culture. Unless otherwise stated, all primary cells and cell lines used in this study were 
maintained in DMEM (Corning, MT-10-13-CV) with the addition of 10% (vol:vol) FBS and 1% Pen Strep 
(Gibco) at 37°C in a 5% CO2 humidified atmosphere. 
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Effect of IκBα siRNA on total NF-κB activation in macrophages. To investigate the possibility 
of activating the classical NF-κB pathway by knocking down the inhibitor of the classical pathway, IκBα, 
siRNA against IκBα was delivered to NGL BMDMs in 12 well plates at 50 nM for 24 hours using MnNP. 
MnNP were fabricated as described in Ch. 2. Free siRNA and empty MnNP were also delivered separately 
as controls. Total NF-κB activation was assessed at various time points by luciferase assay.  
qRT-PCR of BMDMs transfected with p52/p100 and IκBα siRNA. Wild type BMDMs were 
plated in 6-well plates at a density of 2,000,000 cells per well (approximately 210,000 cells/cm2). Each 
sample was taken from a different mouse, for a total of 3 biological replicates, with 3 experimental 
replicates per biological replicate. The cells were transfected using MnNP for 24 hours with IκBα, 
p52/p100, or scrambled siRNA, with and without TNF-α stimulation. After transfection, mRNA was 
collected from the cells for qRT-PCR. 
Preparation of mRNA for qRT-PCR. mRNA was extracted from cells using Qiagen’s RNeasy 
kit and DNA was removed from the samples using Life Technologies’ DNA-free kit. cDNA was prepared 
from the isolated mRNA using dNTPs from Roche and random hexamers and superscript II reverse 
transcriptase from Life Technologies. qRT-PCR was performed with SYBR green real-time PCR master 
mix (Life Technologies) using Applied Biosystems’ Step One Plus real-time PCR systems hardware and 
software. The Step One Plus software was used to automatically calculate optimized baseline and threshold 
values. Differences in cDNA levels were calculated using the ΔΔCt method with GAPDH as an internal 
control. The sequences used for qRT-PCR are summarized in Table 3.1. 
Table 3.1: qRT-PCR primer sequences 
Gene Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
GAPDH TGAGGACCAGGTTGTCTCCT CCCTGTTGCTGTAGCCGTAAT 
IκBα TGAAGGACGAGGAGTACGAGC TTCGTGGATGATTGCCAAGTG 
p100 GCTTCTCAGCTTTCCTTCGAGCTA GCAAATAAACTTCGTCTCCACCGC 
IKKβ GCTGGAGCAGAGAAATGTCAGAGT CTCAGGAACAATCAAAGCGTGCAG 
CXCL9 GTGGTGAAATGGAAAGATCAGGGC AAGAGAGAAATGGGTTCCCTGGAG 
IL-10 ACCTGCTCCACTGCCTTGCT GGTTGCCAAGCCTTATCGGA 
CD206 CAAGGAAGGTTGGCATTTGT CCTTTCAGTCCTTTGCAAGC 
CCL3 TGCCCTTGCTGTTCTTCTCT GATGAATTGGCGTGGAATCT 
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Statistical analysis. Paired comparisons were made using a two-tailed T-test to determine 
significant differences between samples. For figure 3.4, multiple comparisons were made by first 
performing single factor ANOVA to confirm significant differences within the groups, then post hoc 
analysis was performed using two-tailed T-tests, for six total comparisons (30% chance for type I error). 
Results and Discussion 
Target protein selection for strategic manipulation of NF-κB to produce therapeutically 
relevant changes in TAM phenotype. My experiments screening siRNA sequences for NF-κB proteins 
show that it is possible to knock down total NF-κB activity with MnNP delivered siRNA. Although siRNA 
sequences for IKKβ, p65, and p52 all resulted in significant knockdown, it is important to establish whether 
or not these proteins will be efficacious targets. Although p65 is implicated in producing smoldering 
inflammation in the tumor microenvironment, it is also responsible for survival signaling in macrophages. 
p65 is not an optimum target because knocking down p65 could potentially induce apoptosis in the 
macrophages being targeted for phenotypic modification.68, 72  
Viable targets for therapeutic siRNA knockdown ideally should also express increased amounts of 
the target mRNA while in the pathological state. qRT-PCR of TNF-α stimulated BMDMs indicates that 
while levels of p52 mRNA are increased upon exposure to TNF-α, levels of IKKβ do not significantly 
increase (Figure 3.1). There are multiple potential explanations for why increased levels of IKKβ mRNA 
were not detected. It is known that the classical NF-κB pathway is rapidly activated within minutes of 
stimulation, while alternative activation is more gradual.66, 73, 74 If there is an increase in IKKβ mRNA, it is 
possible that the increase is rapidly induced, then rapidly degraded. Another alternative is that there is 
already enough IKKβ protein active in the cell to activate enough p50:p56 homodimers and induce a 
classical NF-κB response; increased production of IKKβ may not be necessary. Regardless of the reason, 
this lack of increase in IKKβ mRNA makes it a poor target for siRNA mediated knockdown. In addition, 
there are significant non-NF-κB functions of IKKβ, and knocking down this protein could potentially have 
off-target effects.3  
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 p52 is a viable target for knocking down alternative NF-κB activity in TAMs. Neither IKKβ nor 
p65 are attractive targets for siRNA mediated knockdown aimed at reducing the smoldering inflammation 
produced by TAMs. However, decreasing the smoldering inflammation from these cells is not the only 
therapeutic option. If the full inflammatory potential of the TAMs could be reactivated, these cells could 
promote a potent immune response at the site of the tumor by releasing inflammatory cytokine and inducing 
apoptosis and by recruiting cytotoxic immune cells of innate and adaptive immune system. This effect could 
be achieved by strongly activating the classical NF-κB pathway in TAMs.  
 Although delivering siRNA with MnNP was initially designed to knockdown NF-κB activity, it 
should theoretically be able to activate the classical pathway as well. Activation of transcriptional pathways 
by siRNA has been reported before, but only as an undesirable, off-target side effect. Because the IκBα 
protein inhibits activation of the classical pathway, knocking down this protein could potentially increase 
classical NF-κB activation. Activation of a key transcriptional pathway would be a novel approach to 
manipulating cell phenotype for immunoengineering. To test this hypothesis, NGL BMDMs were 
transfected with MnNP delivered siRNA against IκBα for 24 hours, and total NF-κB activation was 
measured at multiple time points during transfection. Figure 3.2 shows that while free siRNA did not induce 
 
Figure 3.1: qRT-PCR of TNF-α stimulated BMDMs and unstimulated 
BMDMs. Activation is confirmed by significant increase in CCL3 
mRNA and significant decrease in IL-10 mRNA. Levels of p100/p52 
mRNA significantly increase following 6 hours of TNF-α stimulation, 
but the amount of IKKβ mRNA does not significantly increase. * : P < 
0.05, ** : P < 0.005. 
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activation of NF-κB, and empty particles had a very minor immunogenic effect, delivery of IκBα siRNA 
by MnNP induced significant activation of NF-κB without any other source of stimulation. 
 
 This result shows a novel approach to therapeutic RNAi: using knockdown to increase activation 
rather than decrease activation of a transcriptionally active pathway. Knocking down the inhibitor of the 
classical NF-κB pathway increases total NF-κB activity, but it is important to understand if this knockdown 
is physiologically and therapeutically relevant. In order to understand what affect IκBα knockdown in 
macrophages might have on tumor cells, an IκBα knockout macrophage line was co-cultured with 
fluorescently labeled tumor cells (PYL) for 3 days and the co-culture was imaged at <1 and 3 days (Images 
courtesy of Oleg Tikhomirov). Figure 3.3 shows the IκBα knockout (IκBα k/o) macrophage/PYL tumor 
cell co-culture compared to a wild type macrophage line, also at 3 days co-culture with PYL cells. After 3 
days, the wild type macrophages exist in stable co-culture with the tumor cells and there are no overt, 
morphological signs of cytotoxicity in ether cell type. However, even earlier than 1 day post co-culture, 
there are signs that the IκBα k/o macrophages are mediating some form of tumor cell cytotoxicity. The 
IκBα k/o macrophages appear to form adhesion complexes with the tumor cells and pull on the membrane 
of the cells. Adhesion complexes are known to play an important part in mechanisms of classically activated 
 
Figure 3.2: Activation of NF-κB in NGL BMDMs by MnNP delivery of IκBα siRNA without 
any other form of stimulation or activation. NF-κB activity is significantly increased as early as 
12 hours following transfection with IκBα by MnNP, and activity has more than doubled 24 hours 
after transfection (** : P ≤. 0.001). There is some small activation caused by delivery of unloaded 
MnNP polymer after 24 hours, but this activation is significantly less than that mediated by 
delivery of both MnNP and IκBα (P = 0.005). 
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macrophage cytotoxicity. Furthermore, the k/o macrophages appear to destroy the cytoplasmic 
compartment of the tumor cells, and by 3 days, only fragments of the tumor cells are left; The IκBα k/o 
macrophages have mediated some form of extracellular lysis of the tumor cells.75, 76  
  
 qRT-PCR of BMDM transfected with NF-κB specific siRNA sequences by MnNP. After it was 
determined that it was possible to activate NF-κB by knocking down the inhibitor of the classical pathway 
and that IκBα k/o macrophages can be cytotoxic to tumor cells, the mRNA from BMDMs transfected with 
IκBα siRNA by MnNP was analyzed for potential anti-tumor indications. Figure 3.4A shows that levels of 
mRNA for IκBα are significantly decreased following transfection with IκBα siRNA, indicating successful 
knockdown at the mRNA level of IκBα. This can be contrasted to IKKβ as a classical pathway target, which 
I predict would not be an optimal target for mRNA level knockdown.  
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Figure 3.4: qRT-PCR of IκBα siRNA transfected BMDMs. In all cases, ANOVA indicates the presence of significant 
differences in the datasets (P<0.001) (A) IκBα siRNA significantly knocks down IκBα mRNA. Although stimulation with TNF-
α increase IκBα mRNA, this effect is significantly reduced by IκBα siRNA. (B) IκBα siRNA increases mRNA for T-cell 
recruitment cytokine, CXCL9. The increase in CXCL9 mRNA by transfection alone is not significantly different than the 
increase caused by TNF-α alone. (C) IκBα siRNA decreases mRNA for the mannose receptor, CD206, an M2 and TAM 
phenotype marker. The combination of TNF-α and IκBa siRNA results in significantly greater decrease in CD206 mRNA. (D) 
IκBα siRNA decreases mRNA for IL-10, an immunosuppressive cytokine. The decrease in IL-10 mRNA by transfection alone 
is not significantly different than the decrease caused by TNF-α alone, but the combination of the two results in less IL-10 
mRNA than either condition by itself. (E) IκBα siRNA decreases mRNA for p52. TNF-α stimulation of macrophages increases 
levels of p52 mRNA: p52 is a viable target for mRNA level knockdown. Transfection with IκBα siRNA reduces the increase 
in p52 mRNA caused by TNF-α, indicating potentially beneficial cross-talk between the two pathways which could be leveraged 
to act synergistically toward altering the TAM phenotype to an anti-tumor phenotype. † : P ≤ 0.01,  *, + : P ≤ 0.005 
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 Figure 3.4 also shows modifications in the mRNA levels of cancer-context relevant cytokines 
produced by macrophages. IκBα siRNA increase the amount of CXCL9 mRNA in macrophages to a level 
that is not significantly different from levels of CXCL9 mRNA in TNF-α stimulated macrophages. CXCL9 
is a chemotactic signal that recruits CD8+ T-cells and NK cells.77 Furthermore, the combination of IκBα 
siRNA and TNF-α acts in an additive fashion, resulting in significantly more CXCL9 mRNA than either of 
the two treatments alone. Increasing CXCL9 in the tumor microenvironment has been shown to enhance 
antitumor immunity in murine breast cancer models.78 It has also been reported that intermediate CXCL9 
signaling is necessary for T-cells to respond to other recruitment signals, such as IL-12.79 This indicates 
that knockdown of IκBα in TAMs could recruit activated, cytotoxic cells of the innate and adaptive immune 
systems to the tumor microenvironment. The recruitment of T-cells to solid tumors has been the major 
focus of many efforts to induce tumor immunity in several types of cancer.54, 55, 80 Recruitment of T-cells 
by modified macrophages in the tumor is another potential method of activating adaptive tumor immunity. 
 MnNP-delivered IκBα siRNA also decrease levels of phenotypic markers indicating a pro-tumor, 
immunosuppressive macrophage phenotype. Increased levels of the mannose receptor, CD206, in 
macrophages indicates an alternatively activated phenotype and/or a TAM phenotype.12, 29 Both TNF-α and 
IκBα siRNA decrease mRNA for CD206 in macrophages. The combination of the two also significantly 
decreases CD206 mRNA. This effect is particularly important because the mannose receptor is the target 
of the mannose ligand on the MnNP surface. Transfecting macrophages with IκBα siRNA effectively 
decreases the amount of target on the macrophages surface. This effect could ensure that only macrophages 
with a strong TAM phenotype, cells with more CD206 on their surface, have enhanced, endosomal uptake 
of the particles. Ideally, the MnNP would preferentially transfect macrophages with high levels of CD206. 
Transfection would then alter the phenotype of the macrophage toward classical immune activity, reducing 
the amount of CD206 on the cell surface, preventing further, unnecessary transfection. The MnNP would 
then be free to transfect other resident macrophages with high levels of CD206 or other recruited 
macrophages with a TAM phenotype. The MnNP could also potentially act as a surveillance mechanism if 
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there are particles retained extracellularly in the tumor, re-transfecting macrophages if they begin to re-
adopt a TAM phenotype and express CD206 at their surface. 
 IκBα siRNA also decreases IL-10 mRNA in macrophages. IκBα siRNA decreases the amount of 
IL-10 mRNA in macrophages to a level that is not significantly different from levels of IL-10 mRNA in 
TNF-α stimulated macrophages and the combination of IκBα siRNA and TNF-α results in significantly less 
IL-10 mRNA than either of the two treatments alone. IL-10 is a potent immunosuppressive cytokine and is 
implicated in creating the TAM phenotype by paracrine signaling from tumor cells and other TAMs, and 
by autocrine signaling as well.58, 81 IL-10 has been reported to specifically inhibit the classical NF-κB 
pathway by increasing the amount of cytoplasmic p105 and p50:p50 homodimers, and by reducing p65 
translocation into the nucleus.82, 83 Treatment of macrophages with IL-10 reduces classical NF-κB 
responsiveness to stimulating cytokines like LPS and TNF-α by reducing nuclear translocation of p65:p50 
homodimers, which are responsible for much of the classic inflammatory response governed by NF-κB, 
and by increasing translocation of p50:p50 homodimers which strongly inhibit the classical immune 
response.84 In many cases p50 homodimers inhibit transcription of NF-κB gene targets. However, p50 
homodimers are reported to activate production of IL-10 in macrophages.53, 85 Furthermore, IL-10 
stimulation of macrophages does not affect the ability of the alternative NF-κB pathway in these cells to 
respond to TNF-α and other TNF protein family members, many of which are present in the tumor 
microenvironment.83  
These studies indicate that IL-10 creates a powerful feedback loop in TAMs. IL-10 stimulation 
reduces classical NF-κB responsiveness to TNF-α, but does not completely eliminate the effect. This would 
result in much lower levels of inflammatory cytokine production in response to the constant presence of 
inflammatory cytokines in the tumor microenvironment, producing smoldering inflammation. In addition, 
the alternative pathway is free to respond to a smaller subset of these cytokines, activating the tumor-
supportive effect of this pathway. Finally, IL-10 stimulation activates a positive feedback loop of IL-10 
production, effectively locking the macrophages in the TAM phenotype, unless something can disrupt this 
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signaling loop. Transfection with IκBα siRNA not only decreases IL-10 mRNA, but it also increases the 
transfected macrophages’ ability to respond to TNF-α, indicating that it might be an effective therapeutic 
agent for disrupting the IL-10 positive feedback loop and abrogating the TAM phenotype. 
Finally, the results suggest that there is a certain amount of cross-talk between the two pathways 
that could be leveraged to reduce the negative effects of the TAM phenotype. This result is corroborated 
by the fact that mRNA levels of p52, which increase following TNF-α stimulation, are decreased by 
transfection with IκBα siRNA. This effect may be the result of direct or indirect crosstalk, and could indicate 
the potential possibility of decreasing the pro-tumor effects of the alternative NF-κB pathway by knocking 
down the IκBα and activating the classical pathway. 
To confirm that the effects of MnNP delivered siRNA shown in Figure 3.4 were not artifacts caused 
by macrophage interaction with the MnNP transfection agent, MnNP were used to transfect BMDMs with 
a scrambled siRNA sequence following the same protocol. Figure 3.5 shows that there are no significant 
differences between macrophages transfected with scrambled siRNA sequences and untransfected 
macrophages for mRNA for IκBα, p52, CXCL9, and IL-10. There is some significant increase in CD206 
upon uptake of the MnNP. This is consistent with the reported mechanism of CD206 production following 
CD206 binding events. It has been reported that as the number of CD206 binding and endosomal uptake 
events increases, so does production of CD206.86 This increase in receptor production following activation 
helps to explain the rapid recycling of this receptor.87 The small increase in CD206 following MnNP 
delivery highlights the ability of IκBα knockdown to reduce CD206 mRNA: MnNP-delivered, IκBα siRNA 
alone reduces CD206 mRNA by approximately 95%. 
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Conclusions 
 To facilitate delivery NF-κB specific siRNA to tumor associated macrophages, we have developed 
a targeted polymer nanoparticle that encapsulates and protects siRNA sequences. The nanoparticles have a 
mannosylated surface designed to target the mannose receptor, which is upregulated in TAMs and M2 
macrophages. MnNP can deliver efficacious amounts of siRNA for manipulating the NF-κB pathways in 
macrophages and are more specific than commercial transfection agents. The targeting moiety on the 
surface of the particle also enhances transfection efficacy and speed compared to untargeted nanoparticles 
with the same core structure and siRNA loading. I have utilized MnNP-delivered siRNA to accomplish the 
goal of activating classical NF-κB activity by knocking down the inhibitor of the classical pathway, IκBα. 
There have been reports of siRNA activating transcriptional pathways in cells, but this has always been 
seen as an undesirable, off-target effect of transfection in general. Deliberate activation of a specific 
transcriptional pathway by using siRNA to knockdown an inhibitor of the pathway has not been reported 
     
Figure 3.5: qRT-PCR of scrambled siRNA transfected BMDMs. There is no significant 
decrease in mRNA levels between the two groups for IκBα, p52, IL-10 and CXCL9. There is 
a significant increase in CD206 mRNA following culture with MnNP loaded with a scrambled 
siRNA sequence. This is consistent with previous reports that activation and endosomal 
transport of the mannose receptor increases mannose receptor production in macrophages. 
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and is a novel mechanism for manipulating cell phenotype. Following delivery of IκBα siRNA to 
macrophages by MnNP, mRNA for IκBα was decreased and mRNA for a T-cell recruitment cytokine 
CXCL9 was increased. Furthermore, mRNA for the mannose receptor and for IL-10 were decreased, 
indicating a loss of immunosuppressive function and a potential mechanism for disrupting the positive feed-
back loop between TAMs and tumor cells, which is implicated in sustaining the TAM phenotype. In the 
future we hope to utilize this strategy to modulate NF-κB in TAMs in vivo, and activate tumor immunity in 
solid tumors. 
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CHAPTER 4 
 
Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of 
short nucleotide sequences to tumor associated macrophages in vivo 
Introduction 
The tumor supportive stroma has been identified as an attractive target for therapeutic intervention 
in solid tumors. While most tumors exhibit a large degree of cellular heterogeneity, the tumor stroma is 
potentially more homogenous with respect to local stromal cell phenotype.88 Tumor associated 
macrophages (TAMs) are directly involved in establishing a pro-tumorigenic local microenvironment in 
many tumor types and TAM presence is predictive of poor prognosis and survival in mouse models of 
human breast cancer and in multiple human cancers.15, 89 Data show that TAMs are a viable therapeutic 
target in cancer treatment and that ablating these cells can have a powerful anti-tumor effect. Rather than 
ablate these important modulators of immunity, another proposed solution is to target pro-tumor 
macrophages with a therapeutic agent that can alter their behavior to induce an acute, but strong 
immunogenic phenotype capable of stimulating anti-tumor immunity.90, 91 
Systemic delivery of therapeutic nanoparticles is limited by the many mechanisms by which these 
particles are rapidly cleared from circulation. In almost all cases of systemic delivery, most of the 
nanoparticle dose is cleared by the reticuloendothelial system or by the kidneys. Particles can also be non-
specifically taken up by the spleen. Only a small percentage of the dose makes it to the target site, but even 
a small percentage of the total dose can have a therapeutic effect.  Systemic delivery of nanomaterials for 
cancer therapy often relies on passive delivery and retention in tumors, caused by the enhanced permeability 
and retention effect.92 Delivery to the target cell population is often enhanced by adding a targeting moiety 
to the surface, as is the case with the mannosylated nanoparticles used for these studies. Another method 
used to enhance delivery and retention in tumors is to spatially confine the nanoparticle dose in or near the 
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tumor.93 For the in vivo experiments reported here, all nanoparticle doses were delivered to a spatially 
confined compartment using clinically relevant delivery methods (either direct intratumoral injection or 
direct injection into the peritoneum or lung) in order to mitigate the drawbacks associated with systemic 
injection. 
In this study, I build upon previously published work to demonstrate that these MnNP are 
biocompatible in vitro and in vivo at physiologically relevant doses, provide evidence for the efficacy of 
the CD206-targeting mannose ligand on the surface of the particles, and demonstrate the effective delivery 
of protected nucleotides to TAMs. 
Materials and Methods 
Fabrication of nucleotide loaded MnNP. Nucleotide loaded MnNP were fabricated as described 
in Chapter 2. 
 Particle zeta potential measurements. Average nanoparticle zeta potential (ζ) was determined by 
laser Doppler electrophoresis (LDE) using a Malvern Zetasizer Nano ZS (Malvern Inst. Ltd., Malvern, 
UK).  Briefly, siRNA oligomer solution (50 µM, deionized water) was mixed with two times the volume 
of mannosylated nanoparticle solution (4 mg/mL, PBS) and reacted at room temperature to allow 
complexation. Aliquots were removed and diluted approximately 200-fold in molecular biology grade water 
for zeta potential measurement at time points relative to initiation of the nanoparticle-siRNA complexation 
reaction. Zetasizer measurements were performed at 25 °C with a scattering angle of 175°. 
 Cell culture. Unless otherwise stated, all primary cells isolated for use in this study were 
maintained in DMEM (Corning, MT-10-13-CV) with the addition of 10% (vol:vol) FBS and 1% Pen Strep 
(Gibco) at 37°C in a 5% CO2 humidified atmosphere. 
 In vitro biocompatibility measurements.  Bone marrow derived macrophages (BMDMs) were 
made by harvesting bone marrow from wild type mice on an FVB background. The media for these cells 
was supplemented with media from L-129 fibroblasts as a source of M-CSF.42 The bone marrow was 
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cultured for 6 days in the M-CSF supplemented media and the resultant BMDMs were scraped from their 
plates and re-plated as necessary for further experiments. For in vitro viability experiments, BMDMs were 
plated in 12-well plates at a density of 300,000 cells per well (approximately 80,000 cells/cm2). BMDMs 
were transfected for 24 hours at 37°C with MnNP-siRNA complexes with a scrambled siRNA sequence at 
10 nM and 50 nM concentrations of siRNA with accompanying MnNP concentrations as described above, 
with and without 6 hours of TNF-α stimulation (10 ng/ml) following transfection. A second set of BMDMs 
were transfected with the same siRNA using Lipofectamine 2000 (10:1, vol:vol, Lipofectamine:siRNA) 
(Ambion) for 24 hours with and without TNF-α stimulation. 2 minutes of incubation with Triton x-100 was 
used as a negative control for cell membrane viability. To stain cell membranes for an exclusion viability 
assay, samples were incubated with Trypan Blue for 5 minutes, and the number of viable and non-viable 
cells were counted (over 1000 cells per sample, N=3 for each condition). 
 In vivo biocompatibility measurements. All animal experiments were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee. Wild type FVB mice were i.v. injected via the 
retro-orbital route with MnNP-scrambled siRNA complexes (siRNA: scrambled negative control sequence, 
Ambion) at 5 mg/kg of particles every 24 hours for 3 doses. 24 hours after the final injection, blood serum 
was taken from the mice and analyzed at the Vanderbilt Translational Pathology Core Laboratory. Alanine 
transaminase (ALT) and aspartate transaminase (AST) levels were measured as an indicator of hepatic 
function and blood urea nitrogen (BUN) and serum creatinine (CREAT) as an indicator of renal function.  
 In vivo delivery of fluorescently labeled DNA to murine mammary PyMT TAMs. Palpable 
tumors from 12-week old PyMT mice were used to examine the nucleotide delivery efficacy of MnNP in 
vivo. A 21 base pair, Cy3-labled DNA sequence was purchased from Sigma for complexation with MnNP. 
Three ellipsoidal tumors were selected from each mouse from three separate glands with an average tumor 
volume of 5.2 ± 1.9 cm3. Tumors were selected based on their isolation from any other large tumor and on 
uniformity of size and shape. One tumor from each mouse received an injection of MnNP-DNA_Cy3 
complexes into the centroid of the tumor at a dose of 5 mg/kg, one tumor received an equivalent dose of 
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cy3-labeled DNA, and one tumor received a 100 ul PBS injection. The tumors were injected in this fashion 
every 24 hours for three total doses. 24 hours after the final dose, the tumors were removed, homogenized, 
and the TAMs were isolated with a 45 minute rapid adhesion protocol. Cy3 fluorescence was measured in 
each sample with a Tecan Infinite M1000-Pro plate reader as an indicator of DNA delivery with 12 
measurements per well in a filled circular pattern. The data are shown after background subtracting 
fluorescent averages from the tumors receiving MnNP-DNA_Cy3 complexes normalized to the tumor 
samples receiving free DNA_Cy3. 
In vivo delivery of fluorescently labeled DNA to murine solid ovarian tumor TAMs. ID8 cells 
were generously gifted by Drs. D. Khabele and A. Wilson of the Vanderbilt Ingram Cancer Center. Cy5-
labled DNA was purchased from Sigma (21 base pairs). ID8 cells were injected into the peritoneal cavity 
of mature C57B16 female mice (10 million cells per mouse). 60 days after ID8 cell injection, the mice 
began to present with increased total mass and distended abdomens, indicating the beginning stages of 
ascites development. The mice received 2 injections, 24 hours apart of untargeted particles with DNA_cy5 
(5 mg/kg, 3 mice) or mannose receptor targeted particles with DNA_cy5 (5 mg/kg, 3 mice). 24 hours after 
the last injection, the mice were euthanized and the tumors on the peritoneum were removed and 
homogenized. The TAMs were isolated with a 45 minute rapid adhesion protocol. Cy5 fluorescence was 
measured in each sample with a Tecan Infinite M1000-Pro plate reader as an indicator of DNA delivery 
with 12 measurements per well in a filled circular pattern. 
Murine lung metastasis tumor model and delivery of nanoparticles via intubation. 0.5 million 
L129 PyMT tumor cells were injected via tail vein into wildtype FVB mice.43 2 weeks after injection, each 
mouse was anesthetized with isoflurane and placed on a tilted rodent work stand in the supine position and 
restrained in position by an incisor loop. The tongue was extruded using forceps, the mouse intubated, and 
given a 5 mg/kg dose of either MnNP-DNA_Cy5 complexes (n=5) or OHNP-DNA_Cy5 complexes (n=3). 
Control animals received a 60 ul dose of sterile PBS. After the tubing was removed, the mice were observed 
until normal respiration resumed. 
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IVIS imaging of whole lungs. Whole lungs were removed 6 hrs post-injection from mice receiving 
MnNP-DNA_Cy5 via intubation (n=2) or via i.v. injection (n=2), and an untreated control mouse. All lungs 
were tumor bearing. Lungs were perfused and inflated with cold PBS and then imaged for Cy5 fluorescence 
using a Xenogen IVIS 200 bioluminescent and fluorescent imaging system and Living Image software at 
the Vanderbilt University Institute of Imaging Science. 
Isolation of lung cells and flow cytometry. Lungs were perfused with sterile PBS and digested as 
described above. Single cell suspensions were kept at 4°C and incubated with 1% BSA in PBS to reduce 
non-specific antibody binding. The panel of antibodies used in these experiments included CD45-PE-Cy7 
(clone 10-F11), Gr1-Alexa Fluor 700 (clone RB6-8C5), and CD11B-APC (clone M1/70) (all from BD 
Bioscience). Flow cytometry was performed using a BD LSR II flow cytometer (BD Bioscience) and data 
were analyzed with FlowJo software (TreeStar). To identify the myeloid cell subset in the lung homogenate, 
I began by sorting cells based on CD45 expression. To further differentiate cell populations, I sorted cells 
based on the presence of CD11b and the presence or absence of Gr1. I defined the macrophage population 
as being CD45+/CDllb+/Gr1- and both monocytes and polymorphonuclear (PMN) cells as being 
CD45+/CDllb+/Gr1+.94 These simple flow panels allowed us to isolate normal macrophages and TAMs from 
other myeloid cell populations that could potentially uptake delivered nanoparticles through non-specific 
mechanisms.95, 96 
Results and Discussion 
Particle-siRNA complexation and biocompatibility. MnNPs were synthesized as previously 
reported.13  The chemical structure of the particles is shown in Figure 4.1A.  
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 Commercial transfection agents, such as Lipofectamine, possess strong, positive surface charges 
which facilitate their ability to deliver siRNA and other nucleotides into cells. This same surface charge 
renders commercial transfection agents unacceptable for in vivo use; they exhibit low biocompatibility due 
to aggregate formation and cytotoxicity. Strongly cationic structures have the potential to adsorb anionic 
serum proteins and lose function through aggregation or become opsonized and rapidly cleared from the 
blood compartment. Therefore, net surface charge of the formulated delivery system is known to be an 
important determinate of in vivo function. The cationic charges in MnNPs are designed to be largely 
shielded from surface presentation to optimize their potential for in vivo use. The success of this shielding 
strategy was confirmed by the moderately positive zeta potential of approximately +20 mV as measured by 
dynamic light scattering (Figure 4.1B) in comparison with Lipofectamine 2000, a commonly used 
commercial transfection agent with a zeta potential of more than +50 mV. Charge-based considerations are 
of paramount importance in the context of intravascular administration; however, similar considerations 
are operative for the intraperitoneal and tracheal delivery used in these studies. Thus, the low cationicity of 
MnNPs may optimize successful siRNA delivery to TAMs by the routes of administration considered here.  
 
 
Figure 4.1: (A) Schematic representation of the mannosylated endosomal escape 
nanoparticle illustrating the pH-responsive core (red), the siRNA condensing block (blue), 
the modular ‘clickable’ surface (green), and the mannose surface functionalization (purple). 
(B) Zeta potential measurements of MnNP show a significantly milder surface charge as 
compared to commercial transfection agent, Lipofectamine 2000. (P = 0.003, N=3) 
0
10
20
30
40
50
60
70
MnNP Lipofectamine
Z
e
ta
 P
o
te
n
ti
a
l 
(m
V
)
A B
50 
 
Cationic charge mediates strong interactions with anionic cell membranes to facilitate delivery of 
cargo in vitro, but also may destabilize cells and be responsible for dose-limiting toxicity. I determined the 
effect of MnNP on membrane viability in bone marrow derived macrophages (BMDMs) as an in vitro 
measurement of the biocompatibility of the MnNP-siRNA complexes (Figure 4.2). siRNA was delivered 
at low (10 nM) and high (50 nM) concentrations in the presence or absence of a second immunostimulatory 
cytokine, TNF-α (10 ng/ml), a common tumor promoter in the tumor microenvironment.97, 98 After 24 hours 
of incubation with MnNP-siRNA there was no significant decrease in BMDM membrane integrity in 
samples transfected with MnNP as measured by Trypan Blue staining.99 The high siRNA concentration had 
a slight effect on BMDM membrane viability in the context of the addition of TNF-α, but this effect was 
not significant. In contrast, in the presence of TNF-α, transfection with the commercial agent, 
Lipofectamine 2000, resulted in a significant decrease in viability (21-23%). Lipofectamine is a mixture of 
positively charged lipids; the strongly positive surface charge on the lipid transfection complex results in 
an efficacious in vitro transfection agent, but significantly decreased biocompatibility in vivo due to strong 
interactions with the plasma membrane of non-targeted cells.100 In contrast, MnNP-siRNA complexes 
possess only a mildly positive surface charge, resulting in increased biocompatibility and suitability for 
both in vitro and in vivo transfection. 
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 To test in vivo biocompatibility, wild type FVB mice were intravenously (i.v.) injected with MnNP-
scrambled siRNA complexes at 5 mg/kg once daily for 3 consecutive days. 24 hours after the final injection, 
blood serum was analyzed for alanine transaminase (ALT) and aspartate transaminase (AST) levels as an 
indicator of hepatic function and blood urea nitrogen (BUN) and serum creatinine (CREAT) as an indicator 
of renal function. No significant change in liver or kidney function was observed following 3 sequential 
doses every 24 hours with MnNP, consistent with a lack of acute, organ level toxicity (Table 4.1). Average 
serum creatinine was slightly lower than the normal range, but the difference is not large enough to indicate 
renal damage.101 Since I anticipate that MnNPs will clear the cardiovasculature primarily through 
liver/spleen/reticuloendothelial mechanisms and that molecular components from disassembled micelles (if 
any) will be sufficiently small for renal excretion, the lack of significant dysregulation in liver and kidney 
characteristics suggests both nontoxicity and serum stability. 
 
Figure 4.2: Transfection of BMDMs in vitro with MnNP-siRNA complexes results in no significant 
loss in membrane viability, even with secondary stimulation from 10 ng/ml TNF-α stimulation for 6 
hours. There is significant loss in viability associated with the use of Lipofectamine as a transfection 
agent under these conditions. (*, +: P < 0.05, N=3 for each condition) 
 
0
20
40
60
80
100
120
Untreated 0.5% Triton x-100 Lipofectamine MnNP
%
 v
ia
b
il
it
y
10 nM siRNA
50 nM siRNA
10 nM siRNA + TNF-α
50 nM siRNA + TNF-α
* +
* + 
52 
 
 
 
 
 MnNPs deliver fluorescently labeled nucleotides to murine TAMs in vivo. In order to test the 
in vivo efficacy of the TAM-targeted MnNP, I delivered MnNP carrying fluorescently-tagged, scrambled 
DNA strands to murine tumors in several tumor models. PyMT mice have spontaneously developed 
palpable mammary tumors with dimensions ≥ 1 cm at 12 weeks and the tumors have a necrotic core with 
significant immune cell infiltration and TAM population.52, 102 Due to the poorly vascularized nature of this 
tissue, cells and fluid entering the tumor are retained in the local microenvironment longer than they would 
be retained in normal tissue.92, 103 I directly injected MnNP-DNA conjugates into the center of the tumor for 
a well contained depot of particles that would co-localize with TAMs (Figure 4.3A). I observed no adverse 
effects of multiple, direct MnNP injections. 
Formulation with MnNPs significantly increased DNA_Cy3 delivery to TAMs in murine breast 
tumors (Figure 4.3B). Intratumoral injection of a fluorescently labeled DNA mimic of siRNA resulted in 
nearly 2-fold greater TAM uptake compared to unformulated control DNA_Cy3 administered to another 
mammary tumor in the same mouse. These data suggest that the MnNP formulation is interacts with TAMs 
in a persistent way, noting that this study was carried out as three injections, each separated by 24 hours. 
This demonstrates that injecting MnNPs directly into a primary tumor can successfully deliver nucleic acid 
Table 4.1: Analysis of blood serum enzyme levels revealed no significant changes in liver or kidney function in 
mice receiving three, 5 mg/kg i.v. doses of MnNP-siRNA complexes, 24 hours apart. 
 
Mouse Number  
1 2 3 4 Average σ normal range 
ALT (U/L) 37 49 73 105 66 30 26-120 
AST (U/L) 96 86 213 140 133.75 57.80 69-191 
BUN (mg/dL) 21 23 27 23 23.5 2.51 19-34 
CREAT (mg/dL) 0.4 0.3 0.3 0.4 0.35 0.05 0.4-0.6 
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material to TAMs. The direct injection approach avoids the potential issues associated with intravascular 
administration of MnNPs. 
 
 MnNPs facilitated a similar increase in in vivo delivery of DNA_Cy5 to TAMs in a murine 
ovarian tumor model (Figure 4.4).104 The solid tumors in this implanted ovarian tumor model contain a 
significant TAM population and the ascites fluid generated contains a large amount of blood and immune 
cell infiltrate composed largely of TAMs.105-109 Evidence specifically supports mannose interaction of the 
MnNPs with TAMs in peritoneal tumors as DNA_Cy5 fluorescence is significantly elevated following 
MnNP delivery in comparison with identical, but non-mannosylated, hydroxyl-capped NPs. This result 
confirms the persistence of DNA_Cy5 delivery over two intraperitoneal injections spaced 24 hours apart. 
The environment of the ovarian tumors is somewhat unique in that prior to extremely late stages of 
progression, tumors are confined within the peritoneal compartment. This data provides evidence that an 
approach in which MnNPs are injected directly into the peritoneal cavity can successfully deliver nucleic 
acid material to TAMs without the potential complications associated with intravascular delivery. 
 
Figure 4.3: (A) Diagram of mammary tumor injection scheme for PyMT mice. Three isolated tumors from 
each mouse (N=3) were selected based on uniformity of size and shape. The tumors were injected 3 times, 24 
hours apart with MnNP-DNA_Cy3 complexes, free DNA_Cy3, or PBS into the center of each selected tumor. 
The TAMs were isolated from each tumor and analyzed for cy3 fluorescence. (B) There was a statistically 
significant increase in Cy3 fluorescence in TAMs from tumors that received MnNP-DNA_Cy3 as compared to 
non-specific DNA_Cy3 phagocytosis. 
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 The third in vivo model used to demonstrate MnNP targeting of TAMs was a model in which PyMT 
mammary tumor cells are injected via the tail vein to establish tumors in the lungs (Figure 4.5A). This 
simulates primary mammary cells that have seeded into the lungs and established metastatic growth. 
DNA_Cy5 carrying nanoparticles were delivered directly into the metastasis bearing lungs via intubation. 
This delivery method was chosen for multiple reasons: not only are the nanoparticles spatially contained 
within the lungs, but intubation is a clinically relevant delivery method that results in longer lung retention 
of the delivered therapeutic compared to systemic delivery.110 Figure 4.5B shows that 6 hours after 
administration, MnNP delivered via intubation are detected in the lungs in greater amounts than MnNP 
delivered i.v. This image also demonstrates that delivery via intubation perfused the MnNP solution 
throughout the entire lung. Flow cytometry analysis performed 24 hours after particles were delivered after 
particles were delivered via intubation shows that approximately 40% of CD11b+ myeloid cells contain 
DNA_Cy5 formulated with MnNPs (Figure 4.5C). This population is primarily composed of macrophages 
and granulocytes with some dendritic cells (DCs) and natural killer (NK) cells. DNA_Cy5 was detected in 
a relatively small number of non-myeloid cells, on the order of 2% in the same samples of lung homogenate. 
 
Figure 4.4: Cy5 fluorescence is significantly increased in murine 
ovarian tumor TAMs when Cy5-labeled DNA is delivered with 
mannosylated nanoparticles in vivo as compared to labeled DNA 
delivered with non-targeted nanoparticles. (n=3 mice) 
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Furthermore, DNA_Cy5 uptake by CD45+/CDllb+/Gr1- macrophages is significantly increased in this 
model through formulation with MnNP as compared with DNA_Cy5 formulated with untargeted OHNP 
(figure 4.5D). DNA_Cy5 uptake is not enhanced by mannose presentation on the NP corona in PMN cells 
and monocytes (CD45+/CDllb+/Gr1+) (Figure 4.5D); there is no significant difference in DNA_Cy5 
delivery between MnNP and OHNP formulations with these cell types. These results are consistent with 
strong, mannose-dependent delivery to macrophages and weak, non-specific delivery (presumably by 
phagocytosis) to PMN cells and monocytes. Intubation enables direct access to lung tumor TAMs for NPs, 
avoiding NP dilution and other challenges resulting from intravascular administration. This data 
demonstrates that mannose decoration mediates preferential delivery of NPs to TAMs but not non-myeloid 
cell types that are co-located with the TAMs in this model system. 
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The design of siRNA delivery vehicles intended for intravascular administration leading to tissue-
specific accumulation is an enormous, multidimensional challenge. Such a construct must sequester and 
protect siRNA, avoid adverse effects resulting from interactions with serum proteins and the formed 
elements of the blood, possess sufficient blood compartment half-life for robust extravasation and delivery 
in the target tissues and offer a mechanism for preferential retention. Nonspecific toxicity must also be low. 
In addition, once localized, the carrier must facilitate cellular entry and endosomal escape to provide 
optimal conditions for effective intracellular RNAi. Despite the significant and broad potential clinical 
applications of RNAi, these barriers limit practical use of siRNA in humans.  
         
 
Figure 4.5: MnNP have enhanced uptake in TAMs associated with mammary lung metastases using an 
intubation delivery model. (A) Metastases are visualized in the lungs ex vivo following inflation with Bouin’s 
fixative. Tumors appear white against the normal lung, which stains yellow. (B) IVIS imaging of lungs ex vivo 
shows intubation administration of MnNP results in more than 10 times the Cy5 fluorescence vs intravenous 
administration of MnNP as visualized 6 hours after delivery. (C) Flow cytometry reveals minimal uptake of 
MnNP (approximately 2%) in non-myeloid cells. There is significantly more uptake of MnNP in CD11b+ 
myeloid cells. (D) MnNP show 40% increased uptake by macrophages as compared to OHNP. There is no 
significant difference in nanoparticle uptake between MnNP and OHNP in PMN cells and monocytes. 
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Many potential clinical uses of siRNA may be approachable from other, non-intravascular, routes 
of administration. In this study, I assessed the capacity of an advanced nanoscale delivery system, designed 
for siRNA protection, preferential interaction with cells displaying CD206 and endosomal escape to 
facilitate efficient RNAi in models with clinicl relevance using methods that avoid intravascular 
administration.  
This study is the first to demonstrate mannose-mediated preferential siRNA delivery to TAMs in 
vivo. Ex vivo studies inform three subsequent in vivo treatment approaches, each employing local/regional 
routes of administration that avoid the significant obstacles and design challenges associated with 
intravascular administration. Some additional advantages common to NP delivery approaches that are 
confined to local/regional tissues is avoidance of the liver delivery and rapid urinary clearance that are 
significant limiters for successful intravascular administration of siRNA delivery vehicles. Importantly, the 
characterizations obtained in ex vivo experiments with TAMs are predictive of potential in vivo efficacy. 
I demonstrated that formulation of an siRNA surrogate into the MnNP construct enables 
preferential delivery to TAMs following intratumoral injection. Many characteristics likely contribute to 
this result, including the slightly positive zeta potential of the MnNP relative to free polynucleotide and 
protection against enzymatic degradation. In vivo stability and biocompatibility of the MnNP is also inferred 
from this result, consistent with previous studies and confirmed explicitly in this work by a more rigorous, 
intravascular study. Intratumoral administration has potential as an adjuvant therapy for primary, recurrent 
breast cancers, but likely is more suitable for other cancers that can be individually identified and present 
near the skin surface, such as head and neck cancers or melanoma.  
MnNPs administered intraperitoneally effectively deliver nucleotide payloads to TAMs in the 
distributed tumor burden associated with ovarian cancers. This study provides the clearest evidence that 
mannosylation is responsible for TAM selectivity in vivo, in agreement with previous work and the known 
surface display of CD206 on macrophages, especially pro-tumor TAMs. Multiple doses of MnNPs were 
well tolerated. Spatial confinement of the MnNP dose in the peritoneal cavity presumably enhances the 
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opportunity for interaction with ovarian TAMs relative to intravascular dosing through greater proximity 
and longer persistence. The ability of MnNPs to preferentially localize in lung metastasis TAMs following 
intubation delivery implies transport of the nanomaterials from the alveolar side of the tissue into the 
tumors. Mannose-dependent interaction of MnNPs with TAMs is demonstrated from a different perspective 
in this study relative to the ovarian results in that flow cytometry confirms both strong nucleotide delivery 
to TAMs and lack of delivery to non-myeloid cells. All animals tolerated the intubation and delivery of 
MnNPS, despite a brief, acute response to the significant fluid burden administered to the lungs in both 
experimental and control groups. MnNPs reformulated as a more concentrated suspension will be explored 
to minimize the acute response through minimization of the liquid volume required, although careful 
attention must be devoted to the consequent stability of MnNPs in a more concentrated solution. 
Conclusions 
These studies demonstrate the biocompatibility of MnNP both in vitro and in vivo, and provide 
evidence for enhanced TAM-targeting generated through the use of mannose as a targeting ligand on the 
particle surfaces. Here I provide evidence that these MnNP produce no significant toxicity when used in 
vivo. Incubating BMDMs with MnNP did not significantly decrease cell membrane viability and repeated, 
treatments in adult mice creates no acute kidney or liver damage. Furthermore, I showed that MnNP are 
effective at delivering fluorescently-labeled nucleotides to TAMs in spontaneously formed, primary 
mammary tumors. Additionally, mannose-targeting on the surface of the MnNP results in greater delivery 
of labeled nucleotides to ovarian tumor TAMs compared to non-targeted, hydroxyl-capped nanoparticles 
with the same core structure. Future studies will aim to further develop MnNP for biological applications 
and eventual clinical use, specifically utilizing MnNP to deliver active siRNAs to TAMs in vivo to knock 
down specific target proteins in key transcriptional pathways essential for creating the TAM phenotype and 
to activate an immunogenic, anti-tumor phenotype in this macrophage population. 
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CHAPTER 5 
 
Summary and future work  
 The primary focus of my dissertation has been the development, optimization, and utilization of 
mannosylated, endosomal escape nanoparticles (MnNP) to modulate the phenotype of macrophages by 
delivering NF-κB specific siRNA. I hypothesized that by manipulating the NF-κB pathways in 
macrophages it is possible to create anti-tumor characteristics in these cells. I have shown that the MnNP 
effectively deliver functional siRNA to macrophages and that nucleotide delivery is enhanced by the 
targeting moiety, mannose, which targets the mannose receptor on the surface of tissue regenerative and 
tumor associated macrophages. I have also developed a novel method of activating phenotype controlling, 
transcriptional pathways in macrophages by knocking down an inhibitor of the pathway with siRNA. 
Preliminary evidence shows that activation of the classical NF-κB pathway in this manner results in a 
decrease in mRNA for tumor-supportive cytokines and an increase in an important activated T-cell 
recruiting cytokine. Finally, I have shown that these particles are biocompatible both in vitro and in vivo, 
and that the mannosylated particles facilitate enhanced delivery of nucleotide sequences to tumor associated 
macrophages in multiple in vivo murine models of human cancers.  
Tumor associated macrophages (TAMs) have been implicated as one of the most prevalent and 
impactful types of immune cells in the tumor related stroma. TAMs produce an array of cytokines which 
provide support to nearby tumor cells, suppress classical immune activation in the tumor thereby helping 
tumor cells evade immune surveillance, and participate in tumor cell extravasation and metastasis. TAMs 
also display increased amounts of the mannose receptor. By functionalizing the surface of the nanoparticles 
with mannose, it is possible to enhance uptake of the siRNA loaded particles in TAMs and in in vitro cell 
models of TAMs. 
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 In comparative transfection experiments with commercial agents, MnNP performed similarly to 
the commercial agents in transfection and knockdown efficacy, with the additional potential for in vivo use. 
While commercial agents deliver moderate amounts of nucleotide to a large population of cells, MnNP 
deliver greater amounts of nucleotide to a smaller subset of cells, consistent with enhanced delivery to the 
subset of cells expressing greater amounts of the target endosomal receptor. MnNP are also taken up faster 
and in greater amounts than untargeted, hydroxyl-capped nanoparticles (OHNP) with the same core 
structure. 
 I have used MnNP to deliver siRNA to macrophages in vitro in order to validate a novel strategy 
for abrogating the TAM phenotype and activating a classical immune response in macrophages. This 
strategy entails delivering siRNA for the inhibitor of the classical NF-κB pathway to macrophages and 
activating classical NF-κB signaling by knocking down the inhibitor at the mRNA level. qRT-PCR analysis 
indicates that this methodology has the potential to activate T-cell recruitment by these macrophages, 
decrease immunoinhibitory molecules and markers, and increase the macrophages’ ability to respond to 
inflammatory signals. The intent of this therapeutic strategy would ultimately be to disrupt the TAM-
generating, positive feedback loop between macrophages and tumor cells, and activate tumor immunity. 
 During the course of my investigation into the effects of NF-κB mediated manipulation of 
macrophage phenotype, I have collected data documenting the effects of knocking down specific NF-κB 
proteins by targeting the mRNA for these proteins for degradation by activating the RNAi pathway. I have 
also investigated the complex interplay between tumor cells and macrophages, with special focus on the 
contribution that NF-κB modulation makes to the TAM phenotype. Current research into the factors 
affecting TAM-tumor cell interaction tend to either use genomic or proteomic analysis to visualize the 
contribution of hundreds or thousands of factors, or investigates the effects of one or two cytokines in great 
detail. I believe that it is likely that the TAM phenotype is not generated by the activity of one or two 
cytokines acting on tumor-resident macrophages. Also, it is unlikely that every cytokine produced by TAMs 
and tumor cells has the same magnitude of effect on TAM-tumor interactions. One possible future direction 
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for this work is to analyze the different factors contributing to TAM-tumor cell interaction by performing 
meta-analysis of existing work and principle component analysis of the different cytokines known to both 
act on the NF-κB pathways and contribute to the TAM phenotype. MnNP would be a useful tool for 
investigating the effects of knocking down specific components of this system, and analyzing the effects of 
that knockdown. This analysis could result in a functional model of the role NF-κB plays in generating and 
sustaining the TAM phenotype.  
 I have also performed in vivo experiments demonstrating the enhanced uptake of MnNP by 
macrophages in several mouse models of human cancer. MnNP are highly biocompatible both in vitro and 
in vivo. Repeated intravenous doses of MnNP loaded with short nucleotide sequences do not cause acute 
liver or kidney damage in mice. In a spontaneous mouse model of breast cancer, intra-tumoral injections of 
MnNP loaded with fluorescently labeled nucleotides resulted in enhanced uptake of the nucleotides 
compared to phagocytic uptake of the same amount of free nucleotide. In a disseminated, late-stage ovarian 
tumor model, MnNP were taken up by macrophages in the solid tumor implants while there was no 
significant uptake of untargeted particles. This was likely due to non-specific uptake of the OHNP by the 
millions of phagocytic immune cells in the ovarian ascites fluid. Finally, MnNP were delivered via 
intratracheal intubation to mouse lungs in a tail vein injected, lung metastasis model of breast cancer. MnNP 
uptake was enhanced in macrophages compared to OHNP. Granulocytes and monocytes had no preference 
for a specific type of particle, indicating that while these cells internalized the particles through non-specific 
mechanisms, MnNP were taken up through a mannose dependent mechanism. 
 Currently, there is enough evidence to support the suppositions that MnNP-delivered siRNA can 
manipulate macrophage phenotype, and that MnNP are capable of enhanced delivery to TAMs in vivo. The 
next logical step for demonstrating the therapeutic potential of MnNP for macrophage phenotype editing is 
to deliver functional siRNA to TAMs in vivo. Dosing regimens can be informed by previous experiments 
and modification of TAM phenotype could be confirmed by isolating the TAMs from the primary tumors 
or metastases and analyzing macrophage phenotype with a flow cytometry panel and/or genomic analysis. 
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In order to show true therapeutic efficacy, Kaplan-Meier analysis of animal survival following siRNA 
delivery could also be performed. 
 Finally, mannose receptor expressing macrophages are not only implicated in pathological behavior 
in the context of solid tumors. MnNP could be used to target CD206+ macrophages in other pathologies as 
well. For example, a population of M2-like macrophages has recently been implicated in the dysregulation 
of iron homeostasis in adipose tissue. Elucidating the effects of these CD206+ cells could have implications 
for the treatment of obesity, type 2 diabetes, and other metabolic disorders. I am currently working in an 
advisory capacity with a research group led by Dr. Alyssa Hasty in the department of Molecular Physiology 
and Biophysics to facilitate the use of MnNP to investigate the contributions of these adipose macrophages 
to the dysregulation of iron homeostasis. 
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